Methods of treating chronic sinusitis with anti-TSLP antibodies
By administering anti-TSLP antibodies or their antigen-binding fragments directly to the subjects, the problem of symptoms associated with chronic sinusitis and nasal polyps has been solved, resulting in a significant reduction in symptoms and an improvement in quality of life.
Patent Information
- Application Number
- CN202410606448.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-05-16
- Publication Date
- 2024-11-22
AI Technical Summary
Existing treatments for chronic sinusitis have limitations in controlling inflammation, especially in effectively relieving symptoms related to nasal polyps, and some patients still face the risk of recurrence after surgery.
Using anti-thymocyte stromal lymphopoietin (TSLP) antibody or its antigen-binding fragment, a therapeutically effective amount of the drug composition is administered directly to the subject to reduce nasal polyp-related parameters and improve symptoms of chronic sinusitis.
It significantly reduces symptoms such as nasal polyp scores, total symptom scores, nasal congestion, nasal discharge, and loss of smell, improves quality of life, reduces the frequency of systemic glucocorticoid use, and reduces the need for surgery.
Smart Images

Figure BDA0004842169440000151
Abstract
Description
Technical Field
[0001] The present disclosure belongs to the field of biomedicine, and specifically relates to a method for treating chronic sinusitis by administering an anti-TSLP antibody or an antigen-binding fragment thereof. Background Art
[0002] Chronic rhinosinusitis (CRS) is a highly heterogeneous disease characterized by chronic inflammation of the sinus mucosa. Common symptoms include nasal congestion, sticky or mucopurulent nasal discharge, facial pain, and decreased or lost sense of smell. Symptoms lasting for more than 12 weeks are defined as chronic. CRS is closely related to asthma, allergic rhinitis, etc. CRS can be clinically divided into chronic sinusitis with nasal polyps (CRSwNP) and chronic sinusitis without nasal polyps (CRSsNP). The histopathological features of CRSwNP vary among races and regions. CRSwNP patients in East Asia often show eosinophilic inflammation and type 2 inflammation, which are on the rise.
[0003] Nasal polyps (NP) are proliferative masses of tissue that grow on the nasal or sinus mucosa and protrude from the nasal mucosal surface. NP is a Th2 cell-driven inflammatory process that affects the mucosa of the nose and paranasal sinuses. Nasal polyp tissue usually has high levels of IL-5, eosinophil cationic protein (ECP), and eotaxin, which attract and activate eosinophils, so eosinophils and their products are considered to be hallmarks of nasal polyp-related inflammation. Eosinophils are the main inflammatory cells found in nasal polyps, and nasal polyps are also associated with elevated levels of IgE. Common symptoms of NP include nasal obstruction and congestion, reduced or loss of olfactory perception, anterior and posterior rhinorrhea, and facial pain.
[0004] Thymic stromal lymphopoietin (TSLP) is one of the key molecules that mediate allergic reactions. TSLP is mainly expressed by activated lung and intestinal epithelial cells, keratinocytes and fibroblasts. Immune cells such as dendritic cells (DCs) and mast cells can also produce TSLP. TSLP acts on a variety of immune cells, such as dendritic cells (DCs), and forms a complex with the TSLP receptor (TSLPR) on the cell surface, inducing the formation of Th2 cells and promoting the expression of a variety of inflammatory cytokines (IL-4, IL-5, IL-13, etc.). Literature has shown that the TSLP level in nasal polyp tissues of CRSwNP subjects is higher than that of healthy subjects.
[0005] The current treatment of chronic sinusitis focuses on inflammation control, and treatment methods include local or systemic broad-spectrum anti-inflammatory drugs, such as glucocorticoids and macrolides. If drug treatment is ineffective, endoscopic sinus surgery is used. However, some patients still have postoperative recurrence. Therefore, more effective treatment methods are still needed. SUMMARY OF THE INVENTION
[0007] In one aspect, the present disclosure provides a method for treating chronic sinusitis in a subject in need thereof, comprising administering to the subject an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In one aspect, the present disclosure provides a method for treating chronic sinusitis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In one aspect, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof in the preparation of a medicament for treating chronic sinusitis in a subject in need thereof. In one aspect, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof for treating chronic sinusitis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure.
[0008] In one aspect, the present disclosure provides a method for improving one or more nasal polyp-related parameters in a subject in need thereof, comprising administering an anti-TSLP antibody or an antigen-binding fragment thereof to the subject. In one aspect, the present disclosure provides a method for improving one or more nasal polyp-related parameters in a subject in need thereof, comprising administering a therapeutically effective amount of an anti-TSLP antibody or an antigen-binding fragment thereof to the subject. In one aspect, the present disclosure provides the use of an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for improving one or more nasal polyp-related parameters in a subject in need thereof. In one aspect, the present disclosure provides the use of an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure in improving one or more nasal polyp-related parameters in a subject in need thereof, comprising administering a therapeutically effective amount of an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure to the subject.
[0009] In some embodiments, the present disclosure also provides a pharmaceutical composition comprising an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure for treating chronic sinusitis in a subject. In some embodiments, the present disclosure also provides a pharmaceutical composition comprising an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure for improving one or more nasal polyp-related parameters in a subject in need thereof.
[0010] In some embodiments, the chronic sinusitis is chronic sinusitis with nasal polyps (CRSwNP). In some embodiments, the chronic sinusitis is bilateral chronic sinusitis with nasal polyps. In some embodiments, the subject with chronic sinusitis further suffers from asthma. In some embodiments, the subject with chronic sinusitis with nasal polyps further suffers from asthma. In some embodiments, the subject with bilateral chronic sinusitis with nasal polyps further suffers from asthma.
[0011] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 4 weeks (Q4W). In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered at a dose of 12-630 mg each time. DETAILED DESCRIPTION OF THE INVENTION
[0013] Before describing the present disclosure, it should be understood that the present disclosure is not limited to the specific methods and experimental conditions described, because these methods and conditions can be varied. Unless otherwise specified, the terms used in the present disclosure should not be considered to be uncertain or unclear without special definitions, but should be understood according to the common meanings in the art. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments, and the purpose is not to limit. When a trade name appears in the present disclosure, it is intended to refer to the corresponding commodity or its active ingredient.
[0014] As used herein, "about" means within the acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" may mean within 1 or more than 1 standard deviation as practiced in the art. Alternatively, "about" may mean a range of up to ±5%, such as fluctuations within ±2%, within ±1%, or within ±0.5% of a given specific numerical range. When a specific value is given in the present disclosure or claims, unless otherwise indicated, the meaning of "about" should be considered to be within the acceptable error range for that specific value. In this document, unless otherwise indicated, all values of drug doses, times, step parameters, or conditions are modified by "about" by default.
[0015] Treatments for chronic sinusitis
[0016] In one aspect, the present disclosure provides a method for treating chronic sinusitis in a subject in need thereof, comprising administering an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure to the subject. In one aspect, the present disclosure provides a method for treating chronic sinusitis in a subject in need thereof, comprising administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure to the subject. In one aspect, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for treating chronic sinusitis in a subject in need thereof. In one aspect, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the treatment of chronic sinusitis in a subject in need thereof, comprising administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure to the subject. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof may be formulated together with one or more pharmaceutically acceptable excipients to form a suitable pharmaceutical composition for administration to a subject in need thereof.
[0017] The terms "administering" or "administering" refer to the physical introduction of a therapeutic agent into a subject using any of a variety of methods and delivery systems known to those skilled in the art.
[0018] As used herein, the terms "subject," "patient," or "subject" are used interchangeably. The terms "subject," "patient," or "subject" include any human or non-human animal. The term "non-human animal" includes, but is not limited to, vertebrates such as non-human primates, sheep, dogs, and rodents such as mice, rats, and guinea pigs. In some embodiments, the terms "subject," "patient," or "subject" are mammals. In some embodiments, the subject, patient, or subject is a mouse. In some embodiments, the subject, patient, or subject is a human.
[0019] As used herein, "sinusitis" refers to inflammation of the paranasal sinuses, including inflammation of the maxillary sinus, frontal sinus, ethmoid sinus and sphenoid sinus. As used herein, "chronic sinusitis" ("CRS") is a chronic inflammatory disease of the sinus mucosa, with a course of 8 weeks or longer (e.g., more than 12 weeks). CRS is characterized by a combination of any specific symptoms, including but not limited to nasal congestion, sticky or mucopurulent nasal discharge, nasal discharge, nasal itching, dyspnea, reduced or lost sense of smell, anterior and / or posterior epistaxis, headache and / or facial pain and its consequences. The formal diagnosis is based on a sinus computed tomography (CT) scan and / or sinus endoscopy. Based on endoscopic evaluation, CRS can be clinically divided into chronic sinusitis with nasal polyps and chronic sinusitis without nasal polyps. In addition, "sinusitis" described herein also includes conditions with symptoms of rhinitis.
[0020] In some embodiments, the chronic sinusitis is chronic sinusitis with nasal polyps. In some embodiments, the chronic sinusitis is bilateral chronic sinusitis with nasal polyps.
[0021] As used herein, "nasal polyps" are overgrowths of tissue in one or more nasal cavities. About 80% of nasal polyps are highly edematous and filled with eosinophils. Nasal polyps can also exist as fibers, glands, or cysts. Nasal polyps are teardrop-shaped growths that usually form in the nose and / or sinuses, blocking the sinuses and nasal passages.
[0022] Methods to improve nasal polyp-related parameters
[0023] In one aspect, the present disclosure provides a method for improving one or more nasal polyp-related parameters in a subject in need thereof, comprising administering to the subject an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In one aspect, the present disclosure provides a method for improving one or more nasal polyp-related parameters in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In one aspect, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for improving one or more nasal polyp-related parameters in a subject in need thereof. In one aspect, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in improving one or more nasal polyp-related parameters in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof may be formulated with one or more pharmaceutically acceptable excipients to form a suitable pharmaceutical composition for administration to a subject in need thereof.
[0024] Examples of "nasal polyp-related parameters" include, but are not limited to: (1) Nasal Polyp Score (NPS), (2) Total Symptom Score (TSS), including nasal congestion, rhinorrhea (anterior rhinorrhea (i.e., runny nose) and posterior rhinorrhea (i.e., postnasal drip)) and anosmia, (3) Anosmia score, (4) Nasal Congestion Score (NCS), (5) Rhinorrhea score, (6) Nasal Sinus Outcome Test (SNOT-22) score, (7) Lund Mackay score, (8) Sinusitis Visual Analog Scale (VAS) score, (9) Quality of Life (QoL), (10) Nasal Peak Inspiratory Flow (NPIF), (11) Asthma Control Questionnaire (ACQ-6), (12) Pulmonary function parameters, including FEV1, FVC and FEF 25-75, (13) nasal polyp-associated biomarkers, and (14) the proportion of patients who received systemic glucocorticoid (SCS) rescue or surgical treatment during treatment. "Improvement in nasal polyp-associated parameters", "improvement in nasal polyp-associated parameters", and "improvement in one or more nasal polyp-associated parameters" means an increase in NPIF relative to baseline, and / or a decrease in one or more of the following relative to baseline: NPS, nasal congestion score (NCS), rhinorrhea score, anosmia score, TSS, SNOT-22 score, Lund Mackay score, VAS score, ACQ-6 score for patients with asthma. "Improvement in nasal polyp-associated parameters" also means a decrease in the proportion of patients who received systemic glucocorticoid (SCS) rescue or surgical treatment during treatment. "Improvement in nasal polyp-associated parameters" can be expressed as a percentage, for example, the score can be improved by 1% or more, 3% or more, 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, or 80% or more. As used herein, the term "baseline" is used herein in its ordinary sense as understood by those skilled in the art, for example, with respect to a nasal polyp-related parameter, it refers to the value of the nasal polyp-related parameter of the patient before or at the time of administration of the anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure; for example, "baseline" is the average of all measurements over the 7 days prior to administration of the anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure, or the most recent non-missing measurement prior to administration of the anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure.
[0025] To determine whether a certain nasal polyp-related parameter has been "improved," the parameter is quantified at baseline and at a certain time point after administration of the anti-TSLP antibodies or antigen-binding fragments thereof of the present disclosure. For example, the parameter can be quantified at day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10, day 11, day 12, day 14, or week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, week 12, week 13, week 14, week 15, week 16, week 17, week 18, week 19, week 20, week 21, week 22, week 23, week 24, week 25, week 26, week 27, week 28, week 29, week 30, week 31, week 32, week 33, week 34, week 35, week 36, week 37, week 38, week 39, week 40, week 41, week 42, week 43, week 44, week 45, week 46, week 47, week 48, week 49, week 50, week 51, week 52, week 53, week 54, week 55 , week 31, week 32, week 33, week 34, week 35, week 36, week 37, week 38, week 39, week 40, week 41, week 42, week 43, week 44, week 45, week 46, week 47, week 48, week 49, week 50, week 51, week 52, or longer after measuring the nasal polyp-associated parameters. In certain embodiments, the parameters are measured daily (e.g., including but not limited to once or twice daily), weekly, biweekly, or monthly.
[0026] The difference between the value of a nasal polyp-associated parameter at a specific time point after the start of treatment and the value of the nasal polyp-associated parameter at baseline is used to demonstrate whether the nasal polyp-associated parameter has "improved" (e.g., increased or decreased, depending on the specific parameter measured).
[0027] (1) Nasal Polyp Score (NPS)
[0028] In some embodiments, the present disclosure provides a method for reducing NPS in a subject in need thereof, comprising administering to the subject an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides a method for reducing NPS in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing NPS in a subject in need thereof. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing NPS relative to baseline in a subject in need thereof. NPS is assessed by nasal endoscopy as the sum of the left and right nostril scores. The NPS is scored from 0 to 4 points based on the grade of the polyp, with 0 indicating no polyp present, 1 indicating a small polyp in the middle meatus that does not reach below the lower edge of the middle turbinate, 2 indicating a polyp that reaches below the lower edge of the middle turbinate, 3 indicating a large polyp that reaches the lower edge of the turbinate or medial to the middle turbinate, and 4 indicating a large polyp that completely obstructs the lower nasal cavity. The NPS score ranges from 0 to 8 points (4 points per nasal cavity).
[0029] In some embodiments, administration of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in NPS relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in NPS relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in NPS relative to baseline of about 1 to about 8 points, for example, resulting in a decrease in NPS of about 1 point or more, a decrease of about 2 points or more, or a decrease of about 3 points or more. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in NPS relative to baseline of about 1 point, about 1.5 points, about 2 points, about 2.5 points, about 3 points, about 3.5 points, about 4 points, about 4.5 points, about 5 points, about 5.5 points, about 6 points, about 6.5 points, about 7 points, about 7.5 points, about 8 points or more, or a range formed by any of the above values. In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in NPS relative to baseline of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about %, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values.
[0030] In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in NPS relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in NPS relative to baseline of about 1 point, about 1.5 points, about 2 points, about 2.5 points, about 3 points, about 3.5 points, about 4 points, about 4.5 points, about 5 points, about 5.5 points, about 6 points, about 6.5 points, about 7 points, about 7.5 points, about 8 points or more, or a range formed by any of the above values. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in NPS of at least about 1 point relative to baseline.
[0031] A reduction in NPS may be associated with improvements in one or more other nasal polyp-related parameters.
[0032] (2) Total symptom score (TSS)
[0033] In some embodiments, the present disclosure provides a method for reducing TSS in a subject in need thereof, comprising administering to the subject an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides a method for reducing TSS in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing TSS in a subject in need thereof. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing TSS relative to baseline in a subject in need thereof. Scores are performed for three items of nasal congestion, rhinorrhea (including the mean of anterior rhinorrhea (i.e., runny nose) and posterior rhinorrhea (i.e., postnasal drip)) and anosmia, each of which adopts a 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms). TSS is the sum of the scores for nasal congestion, rhinorrhea, and anosmia, ranging from 0 to 9. Nasal symptoms can be measured at fixed times in the morning and / or at night.
[0034] In some embodiments, administration of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in TSS relative to baseline (i.e., a lower number is achieved on the scale). In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in TSS relative to baseline (i.e., a lower number is achieved on the scale). In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in TSS relative to baseline of about 0.5 points, about 1 point, about 1.5 points, about 2 points, about 2.5 points, about 3 points, about 3.5 points, about 4 points, about 4.5 points, about 5 points, about 5.5 points, about 6 points, about 6.5 points, about 7 points, about 7.5 points, about 8 points, about 8.5 points, about 9 points or more, or a range formed by any of the foregoing values. In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in TSS relative to baseline of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about %, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values.
[0035] In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in TSS relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in TSS relative to baseline of about 0.5 points, about 1 point, about 1.5 points, about 2 points, about 2.5 points, about 3 points, about 3.5 points, about 4 points, about 4.5 points, about 5 points, about 5.5 points, about 6 points, about 6.5 points, about 7 points, about 7.5 points, about 8 points, about 8.5 points, about 9 points or more, or a range formed by any of the foregoing values.
[0036] In some embodiments, the present disclosure provides a method for reducing a nasal congestion score in a subject in need thereof, comprising administering to the subject an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides a method for reducing a nasal congestion score in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing a nasal congestion score in a subject in need thereof. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing a nasal congestion score relative to a baseline in a subject in need thereof.
[0037] In some embodiments, administration of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the nasal congestion score relative to baseline (i.e., a lower number is achieved on the scale). In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the nasal congestion score relative to baseline (i.e., a lower number is achieved on the scale). In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the nasal congestion score relative to baseline by about 0.5 points or more, a decrease by about 1 point or more, or a decrease by about 2 points or more. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the nasal congestion score relative to baseline by about 0.5 points, about 1 point, about 1.5 points, about 2 points, about 2.5 points, about 3 points or more, or a range formed by any of the foregoing values. In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in nasal congestion score relative to baseline of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about %, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values.
[0038] In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in nasal congestion score relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in nasal congestion score relative to baseline of about 0.5 points, about 1 point, about 1.5 points, about 2 points, about 2.5 points, about 3 points or more, or a range formed by any of the foregoing values. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in nasal congestion score of at least about 0.5 points relative to baseline.
[0039] In some embodiments, the present disclosure provides a method for reducing rhinorrhea scores in a subject in need thereof, comprising administering to the subject an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides a method for reducing rhinorrhea scores in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing rhinorrhea scores in a subject in need thereof. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing rhinorrhea scores relative to baseline in a subject in need thereof.
[0040] In some embodiments, administration of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the rhinorrhea score relative to baseline (i.e., a lower number is achieved on the scale). In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the rhinorrhea score relative to baseline (i.e., a lower number is achieved on the scale). In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the rhinorrhea score relative to baseline by about 0.5 points or more, a decrease by about 1 point or more, or a decrease by about 2 points or more. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the rhinorrhea score relative to baseline by about 0.5 points, about 1 point, about 1.5 points, about 2 points, about 2.5 points, about 3 points or more, or a range formed by any of the foregoing values. In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in rhinorrhea score relative to baseline of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about %, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values.
[0041] In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in rhinorrhea score relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in rhinorrhea score relative to baseline of about 0.5 points, about 1 point, about 1.5 points, about 2 points, about 2.5 points, about 3 points or more, or a range formed by any of the foregoing values. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in rhinorrhea score of at least about 0.5 points relative to baseline.
[0042] In some embodiments, the present disclosure provides a method for reducing a loss of smell score in a subject in need thereof, comprising administering to the subject an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides a method for reducing a loss of smell score in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing a loss of smell score in a subject in need thereof. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing a loss of smell score relative to a baseline in a subject in need thereof.
[0043] In some embodiments, administration of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the loss of smell score relative to baseline (i.e., a lower number is achieved on the scale). In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the loss of smell score relative to baseline (i.e., a lower number is achieved on the scale). In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the loss of smell score relative to baseline by about 0.5 points or more, a decrease by about 1 point or more, or a decrease by about 2 points or more. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the loss of smell score relative to baseline by about 0.5 points, about 1 point, about 1.5 points, about 2 points, about 2.5 points, or about 3 points, or a range formed by any of the foregoing values. In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in anosmia score relative to baseline of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, 3%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values.
[0044] In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in the loss of smell score relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in the loss of smell score relative to baseline of about 0.5 points, about 1 point, about 1.5 points, about 2 points, about 2.5 points, about 3 points or more, or a range formed by any of the foregoing values. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in the loss of smell score of at least about 0.5 points relative to baseline.
[0045] (3) Nasal Sinus Outcome Test (SNOT-22)
[0046] In some embodiments, the present disclosure provides a method for reducing the SNOT-22 score in a subject in need thereof, comprising administering an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure to the subject. In some embodiments, the present disclosure provides a method for reducing the SNOT-22 score in a subject in need thereof, comprising administering a therapeutically effective amount of an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure to the subject. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing the SNOT-22 score in a subject in need thereof. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing the SNOT-22 score relative to a baseline in a subject in need thereof. SNOT-22 is used to assess the impact of CRS on the quality of life of patients, and the scale has a total of 22 questions, including three dimensions: physiological problems, functional limitations, and emotional outcomes. The score ranges from 0 to 110, with higher scores indicating a greater impact of CRS on health-related quality of life (HRQoL) (Hopkins et al 2009, Clin. Otolaryngol. 34:447-454).
[0047] In some embodiments, administration of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in SNOT-22 score relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in SNOT-22 score relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in SNOT-22 score relative to baseline by at least about 1 point. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in SNOT-22 score relative to baseline by about 1 point, about 2 points, about 3 points, about 4 points, about 5 points, about 6 points, about 7 points, about 8 points, about 9 points, about 10 points, about 11 points, about 12 points, about 13 points, about 14 points, about 15 points, about 16 points, about 17 points, about 18 points, about 19 points, about 20 points, about 21 points, about 22 points, about 23 points, about 24 points, about 25 points, about 26 points, about 27 points, about 28 points, about 29 points, about 30 points, about 40 points or more, or a range formed by any of the above values. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in SNOT-22 score relative to baseline by at least about 8.9 points. In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in SNOT-22 score relative to baseline by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, About 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values.
[0048] In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in SNOT-22 score relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in SNOT-22 score relative to baseline of at least about 1 point. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in SNOT-22 score relative to baseline. About 1 point, about 2 points, about 3 points, about 4 points, about 5 points, about 6 points, about 7 points, about 8 points, about 9 points, about 10 points, about 11 points, about 12 points, about 13 points, about 14 points, about 15 points, about 16 points, about 17 points, about 18 points, about 19 points, about 20 points, about 21 points, about 22 points, about 23 points, about 24 points, about 25 points, about 26 points, about 27 points, about 28 points, about 29 points, about 30 points, about 40 points or more, or a range formed by any of the above values. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in SNOT-22 score of at least about 8.9 points relative to baseline.
[0049] (4) Lund Mackay Rating
[0050] In some embodiments, the present disclosure provides a method for reducing the Lund Mackay score in a subject in need thereof, comprising administering an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure to the subject. In some embodiments, the present disclosure provides a method for reducing the Lund Mackay score in a subject in need thereof, comprising administering a therapeutically effective amount of an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure to the subject. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing the Lund Mackay score in a subject in need thereof. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing the Lund Mackay score relative to a baseline in a subject in need thereof. Using a sinus CT scan, a Lund Mackay score is performed based on the degree of local opacity (including the maxillary sinus, anterior ethmoid sinus, posterior ethmoid sinus, sphenoid sinus, frontal sinus, and ostiomeatal complex). For the Lund Mackay score of the maxillary sinus, anterior ethmoid sinus, posterior ethmoid sinus, sphenoid sinus or frontal sinus, 0 = normal, 1 = partial opacity, 2 = complete opacity; for the Lund Mackay score of the ostiomeatal complex, 0 = not occluded, 2 = occluded. The score is divided into the left and right sinus systems, with each side scoring ranging from 0 to 12 points, and the total score is 0 to 24 points. For patients who currently have a missing ostiomeatal complex (OC) due to previous surgery, a comprehensive score is given based on the location of the previous OC.
[0051] In some embodiments, administration of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in Lund Mackay score relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in Lund Mackay score relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in Lund Mackay score relative to baseline of about 0.2 points, about 0.4 points, about 0.6 points, about 0.8 points, about 1 point, about 1.2 points, about 1.4 points, about 1.6 points, about 1.8 points, about 2 points, about 2.2 points, about 2.4 points, about 2.6 points, about 2.8 points, about 3 points, about 3.2 points, about 3.4 points, about 3.6 points, about 3.8 points, about 4 points, about 5 points, about 6 points, about 7 points, about 8 points, about 9 points, about 10 points or more, or a range formed by any of the above values. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in Lund Mackay score of at least about 1 point relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in Lund Mackay score of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values.
[0052] In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in Lund Mackay score relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in Lund Mackay score relative to baseline. The Mackay score is decreased by 0.2 points, about 0.4 points, about 0.6 points, about 0.8 points, about 1 point, about 1.2 points, about 1.4 points, about 1.6 points, about 1.8 points, about 2 points, about 2.2 points, about 2.4 points, about 2.6 points, about 2.8 points, about 3 points, about 3.2 points, about 3.4 points, about 3.6 points, about 3.8 points, about 4 points, about 5 points, about 6 points, about 7 points, about 8 points, about 9 points, about 10 points or more, or a range formed by any of the above values, relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in Lund Mackay score of at least about 1 point relative to baseline.
[0053] (5) Sinusitis Visual Analog Scale (VAS) score
[0054] In some embodiments, the present disclosure provides a method for reducing a VAS score in a subject in need thereof, comprising administering an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure to the subject. In some embodiments, the present disclosure provides a method for reducing a VAS score in a subject in need thereof, comprising administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure to the subject. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing a VAS score in a subject in need thereof. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing a VAS score relative to a baseline in a subject in need thereof. VAS is used to evaluate the severity of sinusitis symptoms in patients, with a score range of 0 to 10 points, with lower scores representing less impact of sinusitis on the subject's quality of life. 0 points ≤ VAS score ≤ 3 points indicates mild symptoms, 3 < VAS score ≤ 7 indicates moderate symptoms, and 7 < VAS score ≤ 10 indicates severe symptoms.
[0055] In some embodiments, administration of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the VAS score relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the VAS score relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the VAS score relative to baseline of 0.5 to 10 points, or 0.5 to 5 points. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the VAS score relative to baseline of at least 2 points. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the VAS score relative to baseline of about 0.5 points, about 1 point, about 1.5 points, about 2 points, about 2.5 points, about 3 points, about 3.5 points, about 4 points, about 4.5 points, about 5 points or more points, or a range formed by any of the above values. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in the VAS score relative to baseline of at least about 2 points. In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in VAS score relative to baseline of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 3%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values.
[0056] In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in VAS relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in VAS of about 0.5 points, about 1 point, about 1.5 points, about 2 points, about 2.5 points, about 3 points, about 3.5 points, about 4 points, about 4.5 points, about 5 points, or more points relative to baseline, or a range formed by any of the above values. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in VAS of at least about 2 points relative to baseline.
[0057] (6) Quality of life (QoL)
[0058] The efficacy of anti-TSLP antibodies or antigen-binding fragments thereof can be monitored using a variety of QoLs, including the Short-Form-36 (SF-36) and the European Quality of Life 5 Dimensions 5 Levels (EQ-5D-5L).
[0059] The EQ-5D-5L questionnaire includes 5 aspects: mobility, self-care, daily activities, pain / discomfort, and anxiety / depression, and each aspect has 5 levels: no problems, slight problems, some problems, serious problems, and extremely serious problems. Subjects are asked to indicate their current health status by selecting the most appropriate level in the 5 aspects. The questionnaire also includes a visual analog scale, which requires subjects to rate their current health status using a 0-100 scale, where 100 is the best health state imaginable and 0 is the worst health state imaginable.
[0060] SF-36 is a questionnaire used to assess the health status of subjects, including 8 aspects: physical function (PF, a total of 10 items), physical role (RP, a total of 4 items), bodily pain (BP, a total of 2 items), general health (GH, a total of 5 items), vitality (VT, a total of 4 items), social function (SF, a total of 2 items), emotional role (RE, a total of 3 items) and mental health (MH, a total of 5 items). The total physical health measurement (PCS) includes PF, RP, BP and GH, and the total mental health measurement (MCS) includes: VT, SF, RE, MH. For each aspect, the score of each item is coded, summed, and converted to a scale from 0 to 100. The average of the converted scores of the 8 aspects is the total score, and the PCS score and MCS score are averaged by the scores of the corresponding 4 aspects. The high or low score directly reflects the quality of health status. The higher the score, the better the functional status of this aspect and the higher the quality of life.
[0061] (7) Nasal peak inspiratory flow (NPIF)
[0062] In some embodiments, the present disclosure provides a method for increasing NPIF in a subject in need thereof, comprising administering to the subject an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides a method for increasing NPIF in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for increasing NPIF in a subject in need thereof. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for increasing NPIF relative to baseline in a subject in need thereof. NPIF monitors the subject's nasal flow rate by measuring the maximum inspiratory flow rate of both nostrils, assesses the patient's nasal resistance, and is most relevant to the subject's subjective feeling of nasal congestion.
[0063] In some embodiments, administration of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in NPIF relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in NPIF relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in NPIF relative to baseline by about 0.10 L / min, about 0.15 L / min, about 0.20 L / min, about 0.25 L / min, about 0.30 L / min, about 0.35 L / min, about 0.40 L / min, about 0.45 L / min, about 0.50 L / min, about 0.55 L / min, about 0.60 L / min, about 0.65 L / min, about 0.70 L / min, about 0.75 L / min, about 0.80 L / min, about 0.85 L / min or more, or a range formed by any of the foregoing values. In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in NPIF relative to baseline of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about %, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values.
[0064] In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in an increase in NPIF relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in an increase in NPIF relative to baseline of about 0.10 L / min, about 0.15 L / min, about 0.25 L / min, about 0.30 L / min, about 0.40 L / min, about 0.50 L / min, about 0.60 L / min, about 0.70 L / min, about 0.80 L / min, about 0.90 L / min, about 0.90 L / min, about 0.10 L / min, about 0.25 L / min, about 0.50 L / min, about 0.80 L / min, about 0.90 L / min, about 0.8 ... min, about 0.20 L / min, about 0.25 L / min, about 0.30 L / min, about 0.35 L / min, about 0.40 L / min, about 0.45 L / min, about 0.50 L / min, about 0.55 L / min, about 0.60 L / min, about 0.65 L / min, about 0.70 L / min, about 0.75 L / min, about 0.80 L / min, about 0.85 L / min or more, or a range formed by any of the above values.
[0065] (8) Asthma Control Questionnaire (ACQ-6)
[0066] In some embodiments, the present disclosure provides a method for reducing an ACQ-6 score in a subject in need thereof, comprising administering to the subject an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides a method for reducing an ACQ-6 score in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing an ACQ-6 score in a subject in need thereof. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for reducing an ACQ-6 score relative to a baseline in a subject in need thereof. ACQ-6 measures the adequacy of asthma control and changes in asthma control that occur spontaneously or as a result of treatment. The subjects recorded five asthma symptoms (night awakening due to urgency, symptoms during awakening due to urgency, limited activity, shortness of breath, and wheezing) and the use of bronchodilators (e.g., short-acting β2-receptor agonists) on the ACQ-6 using a 7-point scale (ranging from 0 points for complete control to 6 points for severe poor control). Only subjects with concurrent asthma were assessed with the ACQ-6.
[0067] In some embodiments, administration of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in ACQ-6 score relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in ACQ-6 score relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in ACQ-6 score relative to baseline of at least about 0.1 points. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in ACQ-6 score relative to baseline of at least about 0.5 points. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in ACQ-6 score relative to baseline by about 0.1 points, 0.15 points, about 0.2 points, about 0.25 points, about 0.3 points, about 0.35 points, about 0.4 points, about 0.45 points, about 0.5 points, about 0.55 points, about 0.6 points, about 0.65 points, about 0.7 points, about 0.75 points, about 0.8 points, about 0.85 points, about 0.9 points, about 0.95 points, about 1 point or more, or a range formed by any of the foregoing values. In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in ACQ-6 score relative to baseline of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values.
[0068] In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in ACQ-6 score relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in ACQ-6 score relative to baseline of at least about 0.1 points. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in ACQ-6 score of at least about 0.5 points relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in a decrease in ACQ-6 score relative to baseline of about 0.1 points, 0.15 points, about 0.2 points, about 0.25 points, about 0.3 points, about 0.35 points, about 0.4 points, about 0.45 points, about 0.5 points, about 0.55 points, about 0.6 points, about 0.65 points, about 0.7 points, about 0.75 points, about 0.8 points, about 0.85 points, about 0.9 points, about 0.95 points, about 1 point or more, or a range formed by any of the above values.
[0069] (9) Pulmonary ventilation function measurement
[0070] In some embodiments, the present disclosure provides a method for improving pulmonary ventilation function in a subject in need thereof, comprising administering an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure to the subject. In some embodiments, the present disclosure provides a method for improving pulmonary ventilation function in a subject in need thereof, comprising administering a therapeutically effective amount of an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure to the subject. In some embodiments, the present disclosure provides the use of an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure in the preparation of a medicament for improving pulmonary ventilation function in a subject in need thereof. Pulmonary ventilation function measurements include forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and forced mid-expiratory flow (FEF 25-75 ), where FEF 25-75 It refers to the average expiratory flow rate when 25%-75% of vital capacity is exhaled forcefully.
[0071] In some embodiments, administration of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in FEV1 relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in FEV1 relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in FEV1 relative to baseline of at least about 10 mL. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in FEV1 relative to baseline by about 20 mL, about 40 mL, about 60 mL, about 70 mL, about 80 mL, about 90 mL, about 100 mL, about 110 mL, about 120 mL, about 130 mL, about 140 mL, about 150 mL, about 160 mL, about 170 mL, about 180 mL, about 190 mL, about 200 mL, about 210 mL, about 220 mL, about 230 mL, about 240 mL, about 250 mL, about 260 mL, about 270 mL, about 280 mL, about 290 mL, about 300 mL, about 320 mL, about 340 mL, about 360 mL, about 380 mL, about 400 mL, or more, or a range formed by any of the foregoing values. In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in FEV1 relative to baseline of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about %, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values. In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in FEV1 of at least 100-200 mL relative to baseline. In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in FEV1 of at least 100 mL relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in FEV1 of at least 150 mL relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in FEV1 of at least 200 mL relative to baseline.
[0072] In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in an increase in FEV1 relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in an increase in FEV1 of about 10 mL relative to baseline. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in an increase in FEV1 relative to baseline of about 20 mL, about 40 mL, about 60 mL, about 70 mL, about 80 mL, about 90 mL, about 100 mL, about 150 mL, about 160 mL, about 170 mL, about 180 mL, about 190 mL, about 200 mL, about 210 mL, about 220 mL, about 230 mL, about 240 mL, about 250 mL, about 260 mL, about 270 mL, about 280 mL, about 290 mL, about 300 mL, about 310 mL, about 320 mL, about 330 mL, about 340 mL, about 350 mL, about 360 mL, about 370 mL, about 380 mL, about 390 mL, about 400 mL, about 410 mL, about 420 mL, about 430 mL, about 440 mL, about 450 mL, about 460 mL, about 470 mL, about 480 mL, about 490 mL, about 500 mL, about 510 mL, about 520 mL, about 530 mL, about 540 mL 0 mL, about 110 mL, about 120 mL, about 130 mL, about 140 mL, about 150 mL, about 160 mL, about 170 mL, about 180 mL, about 190 mL, about 200 mL, about 210 mL, about 220 mL, about 230 mL, about 240 mL, about 250 mL, about 260 mL, about 270 mL, about 280 mL, about 290 mL, about 300 mL, about 320 mL, about 340 mL, about 360 mL, about 380 mL, about 400 mL, or more, or a range formed by any of the above values. In some embodiments, the subject is treated with an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure for 1 treatment cycle, 2 treatment cycles, 3 treatment cycles, 4 treatment cycles, 5 treatment cycles, 6 treatment cycles, 7 treatment cycles, 8 treatment cycles, 9 treatment cycles, 10 treatment cycles, 11 treatment cycles, 12 treatment cycles, 13 treatment cycles, or more treatment cycles, resulting in an increase in FEV1 of at least 100-200 mL relative to baseline.
[0073] In some embodiments, administration of an anti-TSLP antibody or antigen binding fragment thereof to the subject results in an increase in FVC relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof to the subject results in an increase in FVC relative to baseline. In some embodiments, administration of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof to the subject results in an increase in FVC relative to baseline by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about %, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values.
[0074] In some embodiments, administering an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in FEF 25-75 In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in FEF 25-75 In some embodiments, administering a therapeutically effective amount of an anti-TSLP antibody or antigen-binding fragment thereof to the subject results in FEF 25-75 about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about About 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%, or a range formed by any of the above values.
[0075] (10) Biomarkers related to nasal polyps
[0076] Nasal polyp-associated biomarkers include biomarkers of blood and nasal secretions, including but not limited to one or any combination of IgE, eosinophil count, thymic activation-regulated chemokine (TARC), eotaxin-3, eosinophil cationic protein (ECP), and myeloperoxidase (MPO). In some embodiments of the present disclosure, one or more nasal polyp-associated biomarkers can be detected from a biological sample derived from a subject. Biological samples include but are not limited to one or any combination of the following materials taken from a subject: culture, cells, tissues, blood (e.g., peripheral blood), saliva, nasal secretions, cerebrospinal fluid, pleural fluid, milk, lymph, sputum, semen, needle aspirates, etc. Any method known in the art can be used to obtain biological samples. For example, nasal secretion samples can be obtained from smears, blown secretions, imprints, lavages, wipes, washes, etc.
[0077] In some embodiments, after the anti-TSLP antibody or its antigen-binding fragment is administered to the subject, one or more of the following in the subject is reduced relative to baseline: IgE level, eosinophil count, TARC level, eotaxin-3 level, ECP level, and MPO level. In some embodiments, after the anti-TSLP antibody or its antigen-binding fragment is administered to the subject, one or more of the following in the subject is reduced relative to baseline: IgE level, eosinophil count, TARC level, eotaxin-3 level, ECP level, and MPO level. In some embodiments, after the anti-TSLP antibody or its antigen-binding fragment is administered to the subject, one or more of the following in the subject's peripheral blood is reduced relative to baseline: IgE level, eosinophil count, eotaxin-3 level, ECP level, MPO level, and TARC level. In some embodiments, after administering a therapeutically effective amount of an anti-TSLP antibody or an antigen-binding fragment thereof to the subject, one or more of the following in the subject's peripheral blood is reduced relative to baseline: IgE level, eosinophil count, eotaxin-3 level, ECP level, MPO level, and TARC level. In some embodiments, after administering an anti-TSLP antibody or an antigen-binding fragment thereof to the subject, one or more of the following in the subject's nasal secretions is reduced relative to baseline: IgE level, eosinophil count, ECP level, MPO level, TARC level, and eotaxin-3 level. In some embodiments, after administering a therapeutically effective amount of an anti-TSLP antibody or an antigen-binding fragment thereof to the subject, one or more of the following in the subject's nasal secretions is reduced relative to baseline: IgE level, eosinophil count, ECP level, MPO level, TARC level, and eotaxin-3 level.
[0078] Anti-TSLP antibodies or antigen-binding fragments thereof
[0079] As used herein, the term "antibody" refers to an antigen binding protein having at least one antigen binding domain. The antibodies and fragments thereof disclosed herein may be whole antibodies or any fragments thereof. Therefore, the antibodies and fragments thereof disclosed herein include monoclonal antibodies or fragments thereof and antibody variants or fragments thereof. Examples of antibody and antigen binding fragment fragments thereof include monospecific antibodies, bispecific antibodies, multispecific antibodies, Fab fragments, Fab' fragments, F(ab)'2 fragments, Fv fragments, isolated CDR regions, single-chain Fv molecules (scFv) and other antibody fragments known in the art. The anti-TSLP antibodies and antigen binding fragments thereof disclosed herein may be IgG1, IgG2, IgG3 or IgG4 isotypes. The term "isotype" refers to the antibody species encoded by the heavy chain constant region gene. The anti-TSLP antibodies and antigen binding fragments thereof disclosed herein may be derived from any species, including but not limited to mice, rats, rabbits, primates, llamas and humans. The anti-TSLP antibodies and antigen binding fragments thereof disclosed herein may be murine antibodies, chimeric antibodies, humanized antibodies or fully human antibodies. Unless otherwise specified, the "antibodies" of the present disclosure include whole antibodies and any antigen-binding fragments or single chains thereof. Conventional "whole antibodies" are glycoproteins comprising two heavy (H) chains and two light (L) chains, and the heavy chains and light chains are connected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of three domains, namely CH1, CH2 and CH3. Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain CL. The VH and VL regions can also be divided into hypervariable regions, namely complementary determining regions (CDRs), and framework regions (FRs) with relatively conservative sequences. Each VH and VL consists of three CDRs and four FRs, respectively, from the amino terminus to the carboxyl terminus, respectively: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. At the same time, as those skilled in the art will appreciate, a special "whole antibody", such as a nanobody, has only a heavy (H) chain and no light (L) chain.
[0080] An "antigen-binding fragment" of an antibody refers to one or more fragments of an antibody that retain the function of specifically binding to an antigen (e.g., TSLP). It has been demonstrated that the antigen-binding function of an antibody can be performed by fragments of the entire antibody. Examples of the term "antigen-binding fragment" of an antibody include: (i) Fab fragment: a fragment consisting of V L 、VH The invention relates to a monovalent fragment consisting of a single variable domain and a heavy chain variable region comprising a single variable domain and two constant domains. The invention relates to a monovalent fragment consisting of a single variable domain and a single constant domain comprising a Fab fragment; a monovalent fragment consisting of a CL and CH1 domain; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments connected by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment consisting of the VH domain (see Ward et al., Nature. 341:544-546 (1989)); (vi) an isolated complementarity determining region (CDR); and (vii) a nanobody, a heavy chain variable region comprising a single variable domain and two constant domains. In addition, although the two domains VL and VH of the Fv fragment are encoded by different genes, VH and VL can be connected into a single protein chain by a synthetic linker using a recombinant method, wherein VL and VH are paired to form a monovalent molecule (called single-chain Fv (scFv); see, for example, Bird et al., Science. 242: 423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. 85: 5879-5883 (1988)). These single-chain antibodies are also encompassed in the term antigen-binding fragment. In addition, recombinant polypeptides, fusion proteins, and immunoconjugates comprising the antigen-binding fragment are also encompassed in the term antigen-binding fragment.
[0081] A "chimeric antibody" is an antibody having at least a portion of a heavy chain variable region and at least a portion of a light chain variable region derived from one species; and at least a portion of a constant region derived from another species. For example, in one embodiment, a chimeric antibody may comprise a murine variable region and a human constant region.
[0082] "Humanized antibodies" are antibodies that contain complementary determining regions (CDRs) derived from non-human antibodies and framework regions and constant regions derived from human antibodies. For example, anti-TSLP antibodies may contain CDRs derived from one or more murine antibodies and human framework regions and human constant regions. Exemplary humanized antibodies are provided herein. Additional anti-TSLP antibodies or variants thereof comprising HCDRs and LCDRs provided herein can be produced using any human framework sequence and are also included in the present disclosure. In one embodiment, framework sequences suitable for use in the present disclosure include those that are structurally similar to the framework sequences provided herein. Additional modifications may be made in the framework region to improve the properties of the antibodies provided herein. Such additional framework modifications may include chemical modifications, point mutations to reduce immunogenicity or remove T cell epitopes, or to return mutations to residues in the original germline sequence. In some embodiments, such modifications include those corresponding to the mutations exemplified herein, including back mutations to germline sequences. For example, in one embodiment, one or more amino acids in the human framework region of the VH and / or VL of the humanized antibodies provided herein are backmutated to the corresponding amino acids in the parent murine antibody.
[0083] The term "identity" is also known as consistency. The "percentage (%) identity" of an amino acid sequence refers to the percentage of amino acid residues in the sequence to be compared that are identical to the amino acid residues in the specific amino acid sequence shown in this article, after comparing the sequence to be compared with the specific amino acid sequence shown in this article and introducing spaces if necessary to achieve the maximum sequence identity percentage, and not considering any conservative substitutions as part of the sequence identity. The amino acid sequence alignment of identity can be carried out in a variety of ways within the scope of the art, such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for comparing sequences, including any algorithm required to obtain the maximum alignment in the full length of the comparison sequence.
[0084] According to some embodiments of the present disclosure, the anti-TSLP antibody or its antigen-binding fragment comprises the complementarity determining region (CDR), heavy chain variable region and / or light chain variable region contained in any amino acid sequence of the anti-TSLP antibody or its antigen-binding fragment involved in the patent application documents with publication numbers WO2021043221 or CN113423733.
[0085] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain CDR1 (HCDR1), a heavy chain CDR2 (HCDR2), a heavy chain CDR3 (HCDR3), a light chain CDR1 (LCDR1), a light chain CDR2 (LCDR2) and a light chain CDR3 (LCDR3), wherein HCDR1 comprises the amino acid sequence of HCDR1 in SEQ ID NO:7, HCDR2 comprises the amino acid sequence of HCDR2 in SEQ ID NO:7, HCDR3 comprises the amino acid sequence of HCDR3 in SEQ ID NO:7, LCDR1 comprises the amino acid sequence of LCDR1 in SEQ ID NO:8, LCDR2 comprises the amino acid sequence of LCDR2 in SEQ ID NO:8 and LCDR3 comprises the amino acid sequence of LCDR3 in SEQ ID NO:8, wherein X1 of SEQ ID NO:8 = A or S.
[0086] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises the amino acid sequence of HCDR1 in SEQ ID NO:17, HCDR2 comprises the amino acid sequence of HCDR2 in SEQ ID NO:17, HCDR3 comprises the amino acid sequence of HCDR3 in SEQ ID NO:17, LCDR1 comprises the amino acid sequence of LCDR1 in SEQ ID NO:18, LCDR2 comprises the amino acid sequence of LCDR2 in SEQ ID NO:18 and LCDR3 comprises the amino acid sequence of LCDR3 in SEQ ID NO:18.
[0087] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 of the heavy chain variable region shown in SEQ ID NO:7, and LCDR1, LCDR2 and LCDR3 of the light chain variable region shown in SEQ ID NO:8, wherein X1 of SEQ ID NO:8 = A or S.
[0088] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 of the heavy chain variable region shown in SEQ ID NO:17, and LCDR1, LCDR2 and LCDR3 of the light chain variable region shown in SEQ ID NO:18.
[0089] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof described in the present disclosure comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1 or 11, HCDR2 comprises the amino acid sequence shown in SEQ ID NO:2 or 12, HCDR3 comprises the amino acid sequence shown in SEQ ID NO:3 or 13, LCDR1 comprises the amino acid sequence shown in SEQ ID NO:4 or 14, LCDR2 comprises the amino acid sequence shown in SEQ ID NO:5 or 15, and LCDR3 comprises the amino acid sequence shown in SEQ ID NO:6 or 16. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof described in the present disclosure comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprises the amino acid sequence shown in SEQ ID NO:2, HCDR3 comprises the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprises the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprises the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprises the amino acid sequence shown in SEQ ID NO:6. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof described in the present disclosure comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises the amino acid sequence shown in SEQ ID NO:11, HCDR2 comprises the amino acid sequence shown in SEQ ID NO:12, HCDR3 comprises the amino acid sequence shown in SEQ ID NO:13, LCDR1 comprises the amino acid sequence shown in SEQ ID NO:14, LCDR2 comprises the amino acid sequence shown in SEQ ID NO:15, and LCDR3 comprises the amino acid sequence shown in SEQ ID NO:16.
[0090] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof described in the present disclosure comprises: HCDR1 of the amino acid sequence shown in SEQ ID NO: 1 or 11, HCDR2 of the amino acid sequence shown in SEQ ID NO: 2 or 12, HCDR3 of the amino acid sequence shown in SEQ ID NO: 3 or 13, LCDR1 of the amino acid sequence shown in SEQ ID NO: 4 or 14, LCDR2 of the amino acid sequence shown in SEQ ID NO: 5 or 15, and LCDR3 of the amino acid sequence shown in SEQ ID NO: 6 or 16. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof described in the present disclosure comprises: HCDR1 of the amino acid sequence shown in SEQ ID NO: 1, HCDR2 of the amino acid sequence shown in SEQ ID NO: 2, HCDR3 of the amino acid sequence shown in SEQ ID NO: 3, LCDR1 of the amino acid sequence shown in SEQ ID NO: 4, LCDR2 of the amino acid sequence shown in SEQ ID NO: 5, and LCDR3 of the amino acid sequence shown in SEQ ID NO: 6. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof described in the present disclosure comprises: HCDR1 of the amino acid sequence shown in SEQ ID NO:11, HCDR2 of the amino acid sequence shown in SEQ ID NO:12, HCDR3 of the amino acid sequence shown in SEQ ID NO:13, LCDR1 of the amino acid sequence shown in SEQ ID NO:14, LCDR2 of the amino acid sequence shown in SEQ ID NO:15, and LCDR3 of the amino acid sequence shown in SEQ ID NO:16.
[0091] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises the above-mentioned HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises the above-mentioned HCDR1, HCDR2 and HCDR3.
[0092] The CDR sequences of anti-TSLP antibodies or antigen-binding fragments thereof are shown in Table 1.
[0093] Table 1. CDR sequences of anti-TSLP antibodies or antigen-binding fragments thereof
[0094]
[0095] It will be understood by those skilled in the art that, unless otherwise specified, the term "CDR" or "complementarity determining region" of a given antibody or region thereof (e.g., variable region) should be understood to encompass complementarity determining regions defined by any known scheme. Although Table 1 has shown CDR sequences (wherein the CDR regions shown in SEQ ID NOs: 1-6 are defined by the Kabat numbering system), however, when referring to antibodies defined by specific CDR sequences defined by certain numbering systems of the present disclosure, the scope of the antibodies also encompasses antibodies defined by CDR sequences converted to other arbitrary numbering system definitions (e.g., a combination of one or more of the definitions of AbM, Chothia, IMGT, CCG or Contact, etc., which are well known in the art).
[0096] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain variable region whose amino acid sequence is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:7 or 17. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a light chain variable region having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:8 or 18, wherein X1 of SEQ ID NO:8 = A or S. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:7 or 17, and a light chain variable region having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:8 or 18, wherein X1 of SEQ ID NO:8 = A or S. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:7, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:8, wherein X1 of SEQ ID NO:8 is A or S. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:17, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:18. In some specific embodiments, the amino acid sequence of the heavy chain variable region of the anti-TSLP antibody or antigen-binding fragment thereof is as shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO:8, wherein X1 of SEQ ID NO:8 is A or S. In some specific embodiments, the amino acid sequence of the heavy chain variable region of the anti-TSLP antibody or antigen-binding fragment thereof is as shown in SEQ ID NO:17, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO:18.
[0097] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO: 7. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a light chain variable region of the amino acid sequence shown in SEQ ID NO: 8, wherein X1 of SEQ ID NO: 8 is A. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO: 7, and a light chain variable region of the amino acid sequence shown in SEQ ID NO: 8, wherein X1 of SEQ ID NO: 8 is A. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO: 7, and a light chain variable region of the amino acid sequence shown in SEQ ID NO: 8, wherein X1 of SEQ ID NO: 8 is S. In some specific embodiments, the amino acid sequence of the heavy chain variable region of the anti-TSLP antibody or antigen-binding fragment thereof is as shown in SEQ ID NO: 7, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO: 8, wherein X1 of SEQ ID NO: 8 is A. In some specific embodiments, the amino acid sequence of the heavy chain variable region of the anti-TSLP antibody or antigen-binding fragment thereof is as shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO:8, wherein X1 of SEQ ID NO:8=S.
[0098] QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLEWMGVIDPSDSDTTYNQKF KGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCTRSLDGYYDYWGQGTLVTVSS(SEQ ID NO:7);
[0099] DIQMTQSPSSSLSASVGDRVTITTCRPTENIYSYLAWYQQKPGKX1PKLLIYFARTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPWTFGGGTKVEIK (SEQ ID NO: 8, X1=A or S);
[0100] QVQLQQSGADLVRPGSSVKISCKTSGFAFSSYYMNWVKQRPGQGLEWIGQIYPGDGETNYNGKFKD KATLTADKSSSTVYMQLSSSLTSEDSAVYFCARAGYSDYVYAMDYWGQGTSVTVSS (SEQ ID NO: 17);
[0101] EIVLTQSPALMAASPGEKVTIICSVSSSITSSNLHWYQQKSETSPKPWIYGTSNLASGVPVRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSFPLTFGSGTKLEIK (SEQ ID NO: 18).
[0102] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof may further comprise a constant region of an immunoglobulin, or a fragment, analog, variant or derivative of the constant region. The constant region comprises a heavy chain constant region and a light chain constant region. In some embodiments, the heavy chain constant region comprises the sequence of a human immunoglobulin heavy chain, such as a heavy chain of human IgG1, IgG2, IgG3 and IgG4 or other classes of immunoglobulins, preferably a heavy chain of human IgG1 and IgG4. In some embodiments, the light chain constant region comprises the sequence of a human immunoglobulin light chain, such as a κ light chain of a human immunoglobulin. In some embodiments, the constant region may comprise any modification described in the text, such as insertion, deletion, substitution or chemical modification of amino acids. The C-terminal lysine of the heavy chain constant region may be present or absent. In some embodiments, the constant region comprises a mutation that changes effector function. In some embodiments, any amino acid residue of the constant region may be substituted with an amino acid residue of any allotype.
[0103] In some embodiments, the heavy chain constant region comprises a human IgG1 heavy chain constant region of the amino acid sequence shown in SEQ ID NO: 21, or a human IgG4 heavy chain constant region of the amino acid sequence shown in SEQ ID NO: 22. In some embodiments, the heavy chain constant region comprises a human IgG1 heavy chain constant region of the amino acid sequence shown in SEQ ID NO: 21. In some embodiments, the light chain constant region comprises a human κ light chain constant region of the amino acid sequence shown in SEQ ID NO: 23. In some embodiments, the amino acid sequence of the heavy chain constant region is as shown in SEQ ID NO: 21 or 22. In some embodiments, the amino acid sequence of the light chain constant region is as shown in SEQ ID NO: 23. The C-terminal lysine of the amino acid sequence shown in SEQ ID NO: 21 or 22 may be present or absent.
[0104] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain whose amino acid sequence is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:9 or 19. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a light chain having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:10 or 20, wherein X1 of SEQ ID NO:10 = A or S. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:9 or 19, and a light chain having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:10 or 20, wherein X1 of SEQ ID NO:10 = A or S. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:9, and a light chain of the amino acid sequence shown in SEQ ID NO:10, wherein X1 of SEQ ID NO:10 is A or S. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:19, and a light chain of the amino acid sequence shown in SEQ ID NO:20. In some specific embodiments, the amino acid sequence of the heavy chain of the anti-TSLP antibody or antigen-binding fragment thereof is as shown in SEQ ID NO:9, and the amino acid sequence of the light chain is as shown in SEQ ID NO:10, wherein X1 of SEQ ID NO:10 is A or S. In some specific embodiments, the amino acid sequence of the heavy chain of the anti-TSLP antibody or antigen-binding fragment thereof is as shown in SEQ ID NO:19, and the amino acid sequence of the light chain is as shown in SEQ ID NO:20.
[0105] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain of the amino acid sequence shown in SEQ ID NO: 9. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a light chain of the amino acid sequence shown in SEQ ID NO: 10, wherein X1 of SEQ ID NO: 10 is A. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain of the amino acid sequence shown in SEQ ID NO: 9, and a light chain of the amino acid sequence shown in SEQ ID NO: 10, wherein X1 of SEQ ID NO: 10 is A. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof comprises a heavy chain of the amino acid sequence shown in SEQ ID NO: 9, and a light chain of the amino acid sequence shown in SEQ ID NO: 10, wherein X1 of SEQ ID NO: 10 is S. In some specific embodiments, the amino acid sequence of the heavy chain of the anti-TSLP antibody or antigen-binding fragment thereof is as shown in SEQ ID NO: 9, and the amino acid sequence of the light chain is as shown in SEQ ID NO: 10, wherein X1 of SEQ ID NO: 10 is A. In some specific embodiments, the amino acid sequence of the heavy chain of the anti-TSLP antibody or antigen-binding fragment thereof is as shown in SEQ ID NO:9, and the amino acid sequence of the light chain is as shown in SEQ ID NO:10, wherein X1 of SEQ ID NO:10=S.
[0106] QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLEWMGVIDPSDSDTTYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCTRSLDGYYDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:9);
[0107] DIQMTQSPSSLSASVGDRVTITCRPTENIYSYLAWYQQKPGKX1PKLLIYFARTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC(SEQID NO:10, X1 = A or S);
[0108] QVQLQQSGADLVRPGSSVKISCKTSGFAFSSYYMNWVKQRPGQGLEWIGQIYPGDGETNYNGKFKDKATLTADKSSSTVYMQLSSLTSEDSAVYFCARAGYSDYVYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:19);
[0109] EIVLTQSPALMAASPGEKVTIICSVSSSITSSNLHWYQQKSETSPKPWIYGTSNLASGVPVRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSFPLTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQID NO:20);
[0110] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:21);
[0111] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:22);
[0112] RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:23)。
[0113] In other embodiments, the anti-TSLP antibody or antigen-binding fragment thereof disclosed herein is selected from Tezspire (Tezepelumab) of AstraZeneca and Amgen, Ecleralimab (CSJ-117) of Novartis, AZD-8630 of AstraZeneca, CM326 of Conoya Biopharmaceuticals, HBM9378 of Hebo Pharmaceuticals, SKB378 of Kelun Biotech, QX008N of Quanxin Biopharma, or SHR-1905 of Hengrui Medicine.
[0114] Pharmaceutical composition containing anti-TSLP antibody or antigen-binding fragment thereof
[0115] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof may be formulated with one or more pharmaceutically acceptable excipients to form a suitable pharmaceutical composition. As used herein, "excipient" is used to describe any ingredient other than the active ingredient (e.g., the anti-TSLP antibody or antigen-binding fragment thereof described in the present disclosure). The choice of excipient will depend to a large extent on factors such as the specific mode of administration, the efficacy of the excipient on solubility and stability, and the nature of the dosage form. As used herein, "pharmaceutically acceptable excipients" include any and all excipients, diluents, fillers, binders, disintegrants, solubilizers, stabilizers, colorants, flavorings, surfactants, emulsifiers, buffers, or encapsulating materials that are physiologically compatible. The amount of each excipient may vary within the conventional range in the art.
[0116] In some embodiments, the unit dose of the pharmaceutical composition containing the anti-TSLP antibody or antigen-binding fragment thereof is 60-2100 mg, 210-840 mg, or 210-420 mg of the anti-TSLP antibody or antigen-binding fragment thereof, for example, about 60 mg, about 90 mg, about 120 mg, about 150 mg, about 180 mg, about 210 mg, about 240 mg, about 270 mg, about 300 mg, about 330 mg, about 360 mg, about 390 mg, about 420 mg, about 450 mg, about 480 mg, about 510 mg, about 540 mg, about 570 mg, about 600 mg, about 630 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, about 1000 mg, about 1010 mg, about 10 0 mg, about 690 mg, about 720 mg, about 750 mg, about 780 mg, about 810 mg, about 840 mg, about 870 mg, about 900 mg, about 930 mg, about 960 mg, about 990 mg, about 1020 mg, about 1050 mg, about 1080 mg, about 1200 mg, about 1260 mg, about 1320 mg, about 1440 mg, about 1470 mg, about 1560 mg, about 1680 mg, about 1800 mg, about 1890 mg, about 1920 mg, about 2040 mg, about 2100 mg, or an anti-TSLP antibody or antigen-binding fragment thereof, or a range formed by any of the above values.
[0117] The pharmaceutical composition containing the anti-TSLP antibody or antigen-binding fragment thereof disclosed herein can be in a suitable dosage form, including but not limited to, tablets, lozenges, pills, capsules (e.g., hard capsules, soft capsules, enteric-coated capsules, microcapsules), elixirs, granules, syrups, injections (e.g., preparations suitable for intramuscular, intravenous, intraperitoneal, subcutaneous injections), granules, emulsions, suspensions, solutions, dispersions, and sustained-release preparations for oral or parenteral administration. In some embodiments, the pharmaceutical composition containing the anti-TSLP antibody or antigen-binding fragment thereof is an injection (e.g., a preparation suitable for intramuscular, intravenous, intraperitoneal, subcutaneous injections).
[0118] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0119] The term "pharmaceutical composition" refers to a mixture of one or more active ingredients (e.g., the anti-TSLP antibodies or antigen-binding fragments thereof disclosed herein) and pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration of the active ingredient (e.g., the anti-TSLP antibodies or antigen-binding fragments thereof disclosed herein) to a subject. As used herein, the terms "pharmaceutical composition" and "preparation" have the same meaning and are used interchangeably.
[0120] In a specific embodiment, the pharmaceutical composition containing the anti-TSLP antibody or its antigen-binding fragment is a water-soluble injection. The water-soluble injection includes but is not limited to a water-soluble preparation that has not been lyophilized or a water-soluble preparation reconstituted with a lyophilized powder. In other embodiments, the pharmaceutical composition containing the anti-TSLP antibody or its antigen-binding fragment is a lyophilized preparation. The lyophilized preparation refers to a preparation prepared by a lyophilization process in which the aqueous solution is first frozen, and then the amount of solvent is reduced by sublimation (primary drying process), and then the amount of solvent is reduced by desorption (secondary drying process) until the amount of solvent is a value that no longer supports biological activity or chemical reaction. The lyophilized preparation disclosed herein can also be dried by other methods known in the art, such as spray drying and bubble drying.
[0121] In some embodiments, the concentration of the anti-TSLP antibody or its antigen-binding fragment in the pharmaceutical composition containing the anti-TSLP antibody or its antigen-binding fragment is 30-300 mg / mL, 50-250 mg / mL, 70-200 mg / mL, 90-150 mg / mL, or 120-150 mg / mL. In some embodiments, the concentration of the anti-TSLP antibody or antigen-binding fragment thereof is about 30 mg / mL, about 50 mg / mL, about 70 mg / mL, about 90 mg / mL, about 100 mg / mL, about 110 mg / mL, about 115 mg / mL, about 120 mg / mL, about 125 mg / mL, about 130 mg / mL, about 135 mg / mL, about 140 mg / mL, about 145 mg / mL, about 150 mg / mL, about 170 mg / mL, about 190 mg / mL, about 200 mg / mL, about 210 mg / mL, about 250 mg / mL, or about 300 mg / mL. In some specific embodiments, the concentration of the anti-TSLP antibody or antigen-binding fragment thereof is about 120 mg / mL. In some specific embodiments, the concentration of the anti-TSLP antibody or antigen-binding fragment thereof is about 150 mg / mL.
[0122] In some embodiments, the pharmaceutical composition containing the anti-TSLP antibody or its antigen-binding fragment comprises the anti-TSLP antibody or its antigen-binding fragment, a buffer, an isotonicity regulator / stabilizer, and a surfactant. In a specific embodiment, the pharmaceutical composition containing the anti-TSLP antibody or its antigen-binding fragment is in the form of a liquid pharmaceutical composition (e.g., an injection), which comprises the anti-TSLP antibody or its antigen-binding fragment, histidine, proline, and polysorbate 80.
[0123] dose
[0124] The amount of the anti-TSLP antibodies or antigen-binding fragments thereof of the present disclosure administered to a subject is generally a therapeutically effective amount. The term "treatment" refers to an attempt to alter the natural course of a disease in a treated individual, and may be for the purpose of preventing, ameliorating, or eliminating a disease or one or more symptoms associated with the disease, including but not limited to preventing the occurrence or recurrence of a disease, alleviating symptoms, reducing any direct or indirect pathological consequences of a disease, preventing metastasis of a disease, slowing the rate of progression of a disease, improving or palliating the state of a disease, prolonging the frequency and duration of symptom-free periods, and regressing or improving the prognosis of a disease. The term "therapeutically effective amount" means an amount of the disclosed compound that (i) treats a particular disease, condition, or disorder, (ii) alleviates, ameliorates, or eliminates one or more symptoms of a particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein. The amount of active substance (e.g., an anti-TSLP antibody or antigen-binding fragment thereof of the present disclosure) that constitutes a "therapeutically effective amount" may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the therapeutic agent or combination of therapeutic agents to elicit a desired response in the individual. The therapeutically effective amount can also be routinely determined by one skilled in the art based on his or her own knowledge and this disclosure.
[0125] Administration regimen
[0126] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 1 week (q1w), every 2 weeks (q2w), every 3 weeks (q3w), or every 4 weeks (q4w). In some specific embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 4 weeks. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered at a dose of 12-840 mg, 21-630 mg, 105-630 mg, 210-630 mg, or 210-420 mg each time. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered at about 12 mg, about 21 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 105 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 7 g, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 4 20mg, about 430mg, about 440mg, about 450mg, about 460mg, about 470mg, about 480mg, about 490mg, about 500mg, about 510mg, about 520mg, about 530mg, about 540mg, about 550mg, about 560mg, about 570mg, about 580mg, about 590mg, about 600mg, about 610mg, about 620mg, about 630mg, about 640mg In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered at a dose of about 210 mg or about 420 mg each time. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 1 week, every 2 weeks, every 3 weeks, or every 4 weeks, and each time is administered at a dose of 210-420 mg of the anti-TSLP antibody or antigen-binding fragment thereof.In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 1 week, every 2 weeks, every 3 weeks, or every 4 weeks, each time at a dose of about 210 mg or about 420 mg of the anti-TSLP antibody or antigen-binding fragment thereof. In some specific embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 4 weeks, each time at a dose of about 210 mg or about 420 mg of the anti-TSLP antibody or antigen-binding fragment thereof.
[0127] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 4 weeks as a treatment cycle. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 4 weeks as a treatment cycle. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered on day 1 of each treatment cycle. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 4 weeks as a treatment cycle.
[0128] In some specific embodiments, every 4 weeks is a treatment cycle, and 210-420 mg of an anti-TSLP antibody or an antigen-binding fragment thereof is administered in each treatment cycle. In some specific embodiments, every 4 weeks is a treatment cycle, and about 210 mg or about 420 mg of an anti-TSLP antibody or an antigen-binding fragment thereof is administered in each treatment cycle. In some specific embodiments, every 4 weeks is a treatment cycle, and about 210 mg or about 420 mg of an anti-TSLP antibody or an antigen-binding fragment thereof is administered on day 1 of each treatment cycle.
[0129] The term "flat dose" is used to refer to the dose administered to a patient regardless of the patient's weight or body surface area (BSA). A flat dose is thus specified as an absolute amount of an agent (e.g., an anti-TSLP antibody or antigen-binding fragment thereof) rather than as a mg / kg dose. For example, a 60 kg person and a 100 kg person would receive the same dose of antibody (e.g., 210 mg or 420 mg TSLP antibody).
[0130] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered to a subject at a uniform dose of 1-840 mg, 12-840 mg, 21-840 mg, 105-840 mg, 210-840 mg, 1-630 mg, 12-630 mg, 21-630 mg, 105-630 mg, 210-630 mg, 210-840 mg, 1-420 mg, 12-420 mg, 21-420 mg, 105-420 mg, or 210-420 mg. In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is present in an amount of about 12 mg, about 21 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 105 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200mg, about 210mg, about 220mg, about 230mg, about 240mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290mg, about 300mg, about 310mg, about 320mg, about 330mg, about 340mg, about 350mg, about 360mg, about 370mg, about 380mg, about 390mg, about 400mg, about 410mg, about 420mg , about 430mg, about 440mg, about 450mg, about 460mg, about 470mg, about 480mg, about 490mg, about 500mg, about 510mg, about 520mg, about 530mg, about 540mg, about 550mg, about 560mg, about 570mg, about 580mg, about 590mg, about 600mg, about 610mg, about 620mg, about 630mg, about 640mg, about 650 In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered to a subject at a uniform dose of about 210 mg, about 420 mg, or about 630 mg.
[0131] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered to a subject at a dose of 0.01 to 20 mg / kg, 0.1 to 15 mg / kg, 1 to 15 mg / kg, 2 to 15 mg / kg, 1 to 10 mg / kg, 2 to 10 mg / kg, or 3 to 10 mg / kg of the subject's body weight.
[0132] In some embodiments, the anti-TSLP antibody or antigen-binding fragment thereof is administered in multiple doses or in a single dose.
[0133] As used herein, the term "single dose" refers to the smallest packaging unit containing a certain amount of medicine, for example, if a box of medicine contains seven tablets, then one tablet is a single dose; or a bottle of injection is a single dose. The term "multiple doses" consists of multiple single doses.
[0134] "Unit dose" refers to the dose of active ingredient contained in the smallest packaging unit containing a certain amount of drug. For example, the dose of antibody contained in a bottle of antibody injection is a unit dose.
[0135] Combination therapy
[0136] In some embodiments, the subject is administered one or more additional therapeutic agents prior to, after, or simultaneously with the anti-TSLP antibody or antigen-binding fragment thereof. In some embodiments, the subject has been administered or is being administered one or more additional therapeutic agents prior to the anti-TSLP antibody or antigen-binding fragment thereof. For example, when an additional therapeutic agent is administered "prior to" the anti-TSLP antibody or antigen-binding fragment thereof, the additional therapeutic agent can be administered at least about 72 hours, about 60 hours, about 48 hours, about 36 hours, about 24 hours, about 12 hours, about 10 hours, about 8 hours, about 6 hours, about 4 hours, about 2 hours, about 1 hour, about 30 minutes, about 15 minutes, or about 10 minutes prior to the administration of the anti-TSLP antibody or antigen-binding fragment thereof. When an additional therapeutic agent is administered "after" the anti-TSLP antibody or antigen-binding fragment thereof, the additional therapeutic agent can be administered at least about 10 minutes, about 15 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, or about 72 hours after administration of the anti-TSLP antibody or antigen-binding fragment thereof. Administration "concurrently" with the anti-TSLP antibody or antigen-binding fragment thereof means that the additional therapeutic agent is administered to the subject within less than 10 minutes of (before, after, or simultaneously with) administration of the anti-TSLP antibody or antigen-binding fragment thereof.
[0137] Additional therapeutic agents can be, for example, IL-1 inhibitors, IL-5 inhibitors, IL-5Rα inhibitors, IL-13 inhibitors, TNF inhibitors, IgE inhibitors, nonsteroidal anti-inflammatory drugs, antibiotics, antihistamines, antifungal agents, local decongestants, long-acting β2 receptor agonists, short-acting β2 receptor agonists, long-acting muscarinic antagonists, leukotriene antagonists and / or glucocorticoids. The glucocorticoids can be, for example, nasal glucocorticoids (INCS), inhaled glucocorticoids and / or systemic glucocorticoids. In some embodiments, the additional therapeutic agent is a nasal glucocorticoid, such as furoate mometasone nasal spray (MFNS). In some embodiments, the additional therapeutic agent is an inhaled glucocorticoid, such as fluticasone or budesonide. In some embodiments, the additional therapeutic agent is a long-acting β2 receptor agonist, such as salmeterol or formoterol.
[0138] In some embodiments, the additional therapeutic agent is mometasone furoate nasal spray, which is administered once a day. In some embodiments, the additional therapeutic agent is mometasone furoate nasal spray, which is administered twice a day. In some embodiments, the additional therapeutic agent is mometasone furoate nasal spray, which is administered once a day at a daily dose of 200 μg. In some embodiments, the additional therapeutic agent is mometasone furoate nasal spray, which is administered once a day at a daily dose of 100 μg.
[0139] In some embodiments, the subject has been or is being administered a nasal glucocorticoid prior to receiving the anti-TSLP antibody or antigen-binding fragment thereof. In some embodiments, the subject has been or is being administered mometasone furoate nasal spray prior to receiving the anti-TSLP antibody or antigen-binding fragment thereof.
[0140] In some embodiments, the subject has been or is being administered mometasone furoate nasal spray prior to receiving an anti-TSLP antibody or antigen-binding fragment thereof, the mometasone furoate nasal spray being administered once daily. In some embodiments, the subject has been or is being administered mometasone furoate nasal spray prior to receiving an anti-TSLP antibody or antigen-binding fragment thereof, the mometasone furoate nasal spray being administered twice daily. In some embodiments, the subject has been or is being administered mometasone furoate nasal spray prior to receiving an anti-TSLP antibody or antigen-binding fragment thereof, the mometasone furoate nasal spray being administered once daily at a daily dose of 200 μg. In some embodiments, the subject has been or is being administered mometasone furoate nasal spray prior to receiving an anti-TSLP antibody or antigen-binding fragment thereof, the mometasone furoate nasal spray being administered once daily at a daily dose of 100 μg.
[0141] Mode of administration
[0142] The following does not limit the mode of administration of the anti-TSLP antibodies or antigen-binding fragments thereof disclosed herein.
[0143] The anti-TSLP antibodies or antigen-binding fragments thereof disclosed herein can be administered in various suitable ways, including, but not limited to, oral, parenteral (by intravenous, intramuscular, topical or subcutaneous routes). In some embodiments, the anti-TSLP antibodies or antigen-binding fragments thereof disclosed herein can be administered by injection, such as intravenous or subcutaneous injection, preferably subcutaneous injection. In some embodiments, the anti-TSLP antibodies or antigen-binding fragments thereof disclosed herein can also be absorbed through the epithelium or mucosa (e.g., oral mucosa, rectal and intestinal mucosa, etc.). In some embodiments, the anti-TSLP antibodies or antigen-binding fragments thereof disclosed herein can also be administered, for example, once, multiple times, and / or over one or more extended time periods. In some embodiments, the anti-TSLP antibodies or antigen-binding fragments thereof disclosed herein can also be administered by various known drug delivery systems, including liposome encapsulation, microparticles, microcapsules, controlled release systems, etc.
[0144] Treatment population
[0145] In some embodiments, the subject of chronic sinusitis has previously been treated with corticosteroids (e.g., treatment failed, unsuitable, and / or intolerant). In some embodiments, the subject of chronic sinusitis has previously been treated with systemic corticosteroids (e.g., treatment failed, unsuitable, and / or intolerant). In some embodiments, the subject of chronic sinusitis has previously been treated with glucocorticoids (e.g., treatment failed, unsuitable, and / or intolerant). In some embodiments, the subject of chronic sinusitis has previously been treated with systemic glucocorticoids (e.g., treatment failed, unsuitable, and / or intolerant).
[0146] In some such embodiments, the chronic sinusitis is chronic sinusitis with nasal polyps. In some such embodiments, the chronic sinusitis is bilateral chronic sinusitis with nasal polyps. In some specific embodiments, the patient with bilateral chronic sinusitis with nasal polyps has previously received systemic glucocorticoid treatment (e.g., treatment failure, unsuitability and / or intolerance). In some specific embodiments, the patient with bilateral chronic sinusitis with nasal polyps has failed treatment with a treatment regimen of systemic glucocorticoids. In some specific embodiments, the patient with bilateral chronic sinusitis with nasal polyps has previously received at least 1 course of systemic glucocorticoid treatment, but bilateral chronic sinusitis with nasal polyps still exists. In some specific embodiments, the patient with bilateral chronic sinusitis with nasal polyps is not suitable for and / or intolerant of systemic glucocorticoid treatment.
[0147] As used herein, "treatment failure" is defined as disease persistence or presence, progression, or recurrence during or after the last treatment.
[0148] In some embodiments, the subject with chronic sinusitis has previously received surgical treatment (e.g., treatment failed). In some embodiments, the subject with chronic sinusitis has previously received surgical treatment for nasal polyps (e.g., treatment failed). In some embodiments, the subject with bilateral chronic sinusitis with nasal polyps has previously received surgical treatment for nasal polyps (e.g., treatment failed).
[0149] In some embodiments, the subject of chronic sinusitis has previously received glucocorticoid treatment (e.g., treatment failure, unsuitability and / or intolerance) and nasal polyp surgery (e.g., treatment failure). In some embodiments, the subject of chronic sinusitis has previously received systemic glucocorticoid treatment (e.g., treatment failure, unsuitability and / or intolerance) and nasal polyp surgery (e.g., treatment failure). In some specific embodiments, the patient with bilateral chronic sinusitis with nasal polyps has previously received systemic glucocorticoid treatment (e.g., treatment failure, unsuitability and / or intolerance) and nasal polyp surgery (e.g., treatment failure).
[0150] The methods or uses of the present disclosure include administering a therapeutically effective amount of an anti-TSLP antibody or an antigen-binding fragment thereof of the present disclosure to a subject in need thereof. As used herein, "a subject in need thereof" means a human or non-human animal diagnosed with chronic sinusitis. In some embodiments, the subject in need thereof suffers from chronic sinusitis with nasal polyps (CRSwNP). In some embodiments, the subject in need thereof suffers from bilateral chronic sinusitis with nasal polyps (CRSwNP). In some specific embodiments, the patient with bilateral chronic sinusitis with nasal polyps has previously received at least one course of systemic glucocorticoid treatment, but still has bilateral chronic sinusitis with nasal polyps; and / or the patient with bilateral chronic sinusitis with nasal polyps has received surgical treatment for nasal polyps (e.g., treatment failure) 6 months prior to the administration of an anti-TSLP antibody or an antigen-binding fragment thereof. In some specific embodiments, the patient with bilateral chronic sinusitis with nasal polyps is not suitable for or is intolerant to systemic glucocorticoid treatment; and / or the patient with bilateral chronic sinusitis with nasal polyps has undergone surgical treatment for nasal polyps (e.g., treatment failure) within 6 months prior to administration of the anti-TSLP antibody or its antigen-binding fragment.
[0151] In some embodiments, the subject in need has bilateral chronic sinusitis with nasal polyps (CRSwNP), and the bilateral NPS is at least 5 points out of a maximum of 8 points, and at least 2 points in each nostril. The presence of nasal polyps is confirmed by endoscopy. In some embodiments, the subject's NCS is at least 2 points. In some embodiments, the subject has symptoms such as rhinorrhoea and / or hyposmia or loss of smell for more than 8 weeks. In some embodiments, the subject's SNOT-22 score is at least 7 points, at least 10 points, at least 15 points, at least 20 points, at least 25 points, at least 30 points, at least 35 points, at least 40 points, at least 45 points, or at least 50 points. In some embodiments, the subject's SNOT-22 score is at least 30 points.
[0152] In some embodiments, the subject in need thereof has been treated with a regimen of nasal glucocorticoids (e.g., mometasone furoate nasal spray) for chronic sinusitis with nasal polyps for at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, or longer. In some embodiments, the subject in need thereof has been treated with a regimen of nasal glucocorticoids (e.g., mometasone furoate nasal spray) for chronic sinusitis with nasal polyps for at least 4 weeks.
[0153] In some embodiments, the "subject in need" has been or is being administered one or more additional therapeutic agents (i.e., "background therapy") prior to receiving an anti-TSLP antibody or antigen-binding fragment thereof. A non-limiting example of the "background therapy" is the administration of glucocorticoids to the subject, including nasal glucocorticoids, inhaled glucocorticoids, and systemic glucocorticoids. In some embodiments, the "subject in need" has been or is being administered nasal glucocorticoids prior to receiving an anti-TSLP antibody or antigen-binding fragment thereof. In some embodiments, the "subject in need" has been or is being administered mometasone furoate nasal spray prior to receiving an anti-TSLP antibody or antigen-binding fragment thereof. In some embodiments, the "subject in need" has been administered mometasone furoate nasal spray for at least 4 weeks prior to receiving an anti-TSLP antibody or antigen-binding fragment thereof. In some embodiments, the "subject in need" continues background therapy after receiving an anti-TSLP antibody or antigen-binding fragment thereof. In some embodiments, the "subject in need" continues to be administered mometasone furoate nasal spray after receiving an anti-TSLP antibody or antigen-binding fragment thereof. In some embodiments, the subject in need thereof stops receiving background therapy (eg, immediately or gradually) prior to receiving the anti-TSLP antibody or antigen-binding fragment thereof.
[0154] In some embodiments, the subject in need thereof further suffers from asthma. In some embodiments, the "subject in need thereof" has been administered glucocorticoids, or is being administered glucocorticoids, before receiving the anti-TSLP antibody or its antigen-binding fragment. In some embodiments, the "subject in need thereof" has been administered inhaled glucocorticoids, or is being administered inhaled glucocorticoids, before receiving the anti-TSLP antibody or its antigen-binding fragment. In some embodiments, the "subject in need thereof" has been administered inhaled glucocorticoids before receiving the anti-TSLP antibody or its antigen-binding fragment. In some embodiments, the "subject in need thereof" has been administered inhaled glucocorticoids for at least 4 weeks before receiving the anti-TSLP antibody or its antigen-binding fragment. In some embodiments, the "subject in need thereof" has been administered INCS before receiving the anti-TSLP antibody or its antigen-binding fragment. In some embodiments, the "subject in need thereof" has been administered INCS for at least 4 weeks before receiving the anti-TSLP antibody or its antigen-binding fragment. In some embodiments, the "subject in need thereof" has been administered INCS and a bronchodilator, or is being administered INCS and a bronchodilator, prior to receiving the anti-TSLP antibody or antigen-binding fragment thereof. Non-limiting examples of bronchodilators include short-acting β2 receptor agonists, long-acting β2 receptor agonists, and long-acting muscarinic antagonists.
[0155] Technical Effects
[0156] Typically, administration of the anti-TSLP antibodies or antigen-binding fragments thereof disclosed herein has one or more of the following effects:
[0157] (1) Benefit patients with chronic sinusitis and nasal polyps;
[0158] (2) have a good safety profile (e.g., low incidence and severity of adverse events and serious adverse events, and low risk of adverse reactions);
[0159] (3) provide a treatment that is well tolerated in patients with CRS with nasal polyps;
[0160] (4) Improvement of one or more nasal polyp-related parameters in patients with CRS (e.g., continuous treatment for 1-13 treatment cycles, NPS decreases by ≥1 point from baseline, NCS decreases by ≥0.5 points from baseline, anosmia score decreases by ≥0.5 points from baseline, SNOT-22 score decreases by ≥8.9 points from baseline, VAS score decreases by ≥2 points from baseline, Lund Mackay score decreases by ≥1 point from baseline, the proportion of subjects requiring nasal polyp surgery decreases significantly, and / or the proportion of subjects requiring rescue with systemic glucocorticoids decreases significantly);
[0161] (5) Provide improvement and control of lung function in CRSwNP subjects with comorbid asthma.
[0162] The anti-TSLP antibodies or antigen-binding fragments thereof and treatment regimens disclosed herein have good therapeutic effects in treating chronic sinusitis (eg, CRSwNP).
[0163] For the purpose of description and disclosure, all patents, patent applications and other identified publications are expressly incorporated herein by reference. These publications are provided only because their disclosure precedes the filing date of the present disclosure. All statements regarding the dates of these documents or the representations of the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the correctness of the dates of these documents or the contents of these documents. Furthermore, any reference to these publications herein does not constitute an admission that the publications are part of the common general knowledge in the art in any country.
[0164] The present disclosure also provides the following specific implementation schemes, but the protection scope of the present disclosure is not limited thereto:
[0165] Embodiment 1. Use of an anti-TSLP antibody or an antigen-binding fragment thereof in the preparation of a medicament for treating chronic sinusitis in a subject in need thereof, wherein:
[0166] (1) The anti-TSLP antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises the amino acid sequence of HCDR1 in SEQ ID NO:7, HCDR2 comprises the amino acid sequence of HCDR2 in SEQ ID NO:7, HCDR3 comprises the amino acid sequence of HCDR3 in SEQ ID NO:7, LCDR1 comprises the amino acid sequence of LCDR1 in SEQ ID NO:8, LCDR2 comprises the amino acid sequence of LCDR2 in SEQ ID NO:8 and LCDR3 comprises the amino acid sequence of LCDR3 in SEQ ID NO:8, wherein X1 of SEQ ID NO:8 = A or S;
[0167] (2) the anti-TSLP antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises the amino acid sequence of HCDR1 in SEQ ID NO: 17, HCDR2 comprises the amino acid sequence of HCDR2 in SEQ ID NO: 17, HCDR3 comprises the amino acid sequence of HCDR3 in SEQ ID NO: 17, LCDR1 comprises the amino acid sequence of LCDR1 in SEQ ID NO: 18, LCDR2 comprises the amino acid sequence of LCDR2 in SEQ ID NO: 18 and LCDR3 comprises the amino acid sequence of LCDR3 in SEQ ID NO: 18;
[0168] (3) the anti-TSLP antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 of the heavy chain variable region as shown in SEQ ID NO:7, and LCDR1, LCDR2 and LCDR3 of the light chain variable region as shown in SEQ ID NO:8, wherein X1 of SEQ ID NO:8 = A or S; or
[0169] (4) The anti-TSLP antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 of the heavy chain variable region shown in SEQ ID NO: 17, and LCDR1, LCDR2 and LCDR3 of the light chain variable region shown in SEQ ID NO: 18.
[0170] Embodiment 2. Use of an anti-TSLP antibody or an antigen-binding fragment thereof in the preparation of a medicament for treating chronic sinusitis in a subject in need thereof, wherein the anti-TSLP antibody or the antigen-binding fragment thereof comprises:
[0171] (1) a HCDR1 comprising the amino acid sequence of SEQ ID NO:1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:2, a HCDR3 comprising the amino acid sequence of SEQ ID NO:3, a LCDR1 comprising the amino acid sequence of SEQ ID NO:4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:6; or
[0172] (2) HCDR1 comprising the amino acid sequence shown in SEQ ID NO:11, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:12, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.
[0173] Embodiment 3. The use according to embodiment 1 or 2, wherein the chronic sinusitis is chronic sinusitis with nasal polyps or bilateral chronic sinusitis with nasal polyps.
[0174] Embodiment 4. The use according to any one of embodiments 1-3, wherein the subject further suffers from asthma.
[0175] Embodiment 5. The use according to any one of embodiments 1-4, wherein the anti-TSLP antibody or antigen-binding fragment thereof is administered at a dose of 12-840 mg, 21-630 mg, 105-630 mg, 210-630 mg, or 210-420 mg each time; preferably, the anti-TSLP antibody or antigen-binding fragment thereof is administered at a dose of 210 mg or 420 mg each time.
[0176] Embodiment 6. The use according to any one of Embodiments 1-5, wherein the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 1 week, every 2 weeks, every 3 weeks, or every 4 weeks; preferably, the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 4 weeks.
[0177] Embodiment 7. The use according to any one of Embodiments 1-6, wherein the subject is administered one or more additional therapeutic agents before, after or simultaneously with receiving the anti-TSLP antibody or its antigen-binding fragment; preferably, the subject has been administered or is being administered one or more additional therapeutic agents before receiving the anti-TSLP antibody or its antigen-binding fragment.
[0178] Embodiment 8. The use according to embodiment 7, wherein the additional therapeutic agent is selected from one or more of glucocorticoids, long-acting β2 receptor agonists, short-acting β2 receptor agonists, IL-1 inhibitors, IL-5 inhibitors, IL-5Rα inhibitors, IL-13 inhibitors, TNF inhibitors, IgE inhibitors, non-steroidal anti-inflammatory drugs, antibiotics, antihistamines, antifungal agents, local decongestants, long-acting muscarinic antagonists and leukotriene antagonists; preferably, the glucocorticoid is selected from one or more of nasal glucocorticoids, inhaled glucocorticoids and systemic glucocorticoids.
[0179] Embodiment 9. The use according to Embodiment 7, wherein the subject has been or is being administered nasal glucocorticoids before receiving the anti-TSLP antibody or its antigen-binding fragment; preferably, the subject has been or is being administered mometasone furoate nasal spray before receiving the anti-TSLP antibody or its antigen-binding fragment.
[0180] Embodiment 10. The use according to any one of embodiments 1-9, wherein the anti-TSLP antibody or antigen-binding fragment thereof comprises:
[0181] (1) a heavy chain variable region having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:7, and a light chain variable region having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:8, wherein X1 of SEQ ID NO:8 = A or S; or (2) a heavy chain variable region having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:17, and a light chain variable region having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:18.
[0182] Embodiment 11. The use according to any one of embodiments 1-10, wherein the anti-TSLP antibody or antigen-binding fragment thereof comprises:
[0183] (1) a heavy chain having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:9, and a light chain having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:10, wherein X1 of SEQ ID NO:10 = A or S; or
[0184] (2) a heavy chain having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 19, and a light chain having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 20.
[0185] Embodiment 12. The use according to any one of Embodiments 1-11, wherein the anti-TSLP antibody or antigen-binding fragment thereof is formulated together with a pharmaceutically acceptable excipient.
[0186] Embodiment 13. Use of an anti-TSLP antibody or antigen-binding fragment thereof for the preparation of a medicament for improving one or more nasal polyp-related parameters in a subject in need thereof, wherein:
[0187] (1) The anti-TSLP antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises the amino acid sequence of HCDR1 in SEQ ID NO:7, HCDR2 comprises the amino acid sequence of HCDR2 in SEQ ID NO:7, HCDR3 comprises the amino acid sequence of HCDR3 in SEQ ID NO:7, LCDR1 comprises the amino acid sequence of LCDR1 in SEQ ID NO:8, LCDR2 comprises the amino acid sequence of LCDR2 in SEQ ID NO:8 and LCDR3 comprises the amino acid sequence of LCDR3 in SEQ ID NO:8, wherein X1 of SEQ ID NO:8 = A or S;
[0188] (2) the anti-TSLP antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises the amino acid sequence of HCDR1 in SEQ ID NO: 17, HCDR2 comprises the amino acid sequence of HCDR2 in SEQ ID NO: 17, HCDR3 comprises the amino acid sequence of HCDR3 in SEQ ID NO: 17, LCDR1 comprises the amino acid sequence of LCDR1 in SEQ ID NO: 18, LCDR2 comprises the amino acid sequence of LCDR2 in SEQ ID NO: 18 and LCDR3 comprises the amino acid sequence of LCDR3 in SEQ ID NO: 18;
[0189] (3) the anti-TSLP antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 of the heavy chain variable region as shown in SEQ ID NO:7, and LCDR1, LCDR2 and LCDR3 of the light chain variable region as shown in SEQ ID NO:8, wherein X1 of SEQ ID NO:8 = A or S; or
[0190] (4) The anti-TSLP antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 of the heavy chain variable region shown in SEQ ID NO: 17, and LCDR1, LCDR2 and LCDR3 of the light chain variable region shown in SEQ ID NO: 18.
[0191] Embodiment 14. Use of an anti-TSLP antibody or an antigen-binding fragment thereof in the preparation of a medicament for improving one or more nasal polyp-related parameters in a subject in need thereof, wherein the anti-TSLP antibody or the antigen-binding fragment thereof comprises:
[0192] (1) a HCDR1 comprising the amino acid sequence of SEQ ID NO:1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:2, a HCDR3 comprising the amino acid sequence of SEQ ID NO:3, a LCDR1 comprising the amino acid sequence of SEQ ID NO:4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:6; or
[0193] (2) HCDR1 comprising the amino acid sequence shown in SEQ ID NO:11, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:12, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.
[0194] Embodiment 15. The use according to embodiment 13 or 14, wherein the subject suffers from chronic sinusitis; preferably chronic sinusitis with nasal polyps or bilateral chronic sinusitis with nasal polyps.
[0195] Embodiment 16. The use according to any one of embodiments 13-15, wherein the subject further suffers from asthma.
[0196] Embodiment 17. The use according to any one of embodiments 13-16, wherein the nasal polyp-related parameters include NPS, TSS, nasal congestion score, rhinorrhea score, anosmia score, SNOT-22 score, Lund Mackay score, VAS score, NPIF, ACQ-6 score, and / or the proportion of patients who received systemic corticosteroid (SCS) rescue or surgical treatment during treatment.
[0197] Embodiment 18. The use according to Embodiment 17, wherein administration of the anti-TSLP antibody or antigen-binding fragment thereof to the subject results in an increase in NPIF relative to baseline.
[0198] Embodiment 19. The use according to embodiment 17, wherein administration of the anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in NPS, TSS, nasal congestion score, rhinorrhoea score, anosmia score, SNOT-22 score, Lund-Mackay score, VAS score and / or ACQ-6 score relative to baseline.
[0199] Embodiment 20. The use according to embodiment 19, wherein administration of the anti-TSLP antibody or antigen-binding fragment thereof to the subject results in a decrease in NPS of 1 point, 1.5 points, 2 points, 2.5 points, 3 points, 3.5 points, 4 points, 4.5 points, 5 points, 5.5 points, 6 points, 6.5 points, 7 points, 7.5 points, or 8 points relative to baseline.
[0200] Embodiment 21. The use according to any one of embodiments 13-20, wherein after administration of the anti-TSLP antibody or antigen-binding fragment thereof to the subject, one or more of the following is reduced: IgE level, eosinophil count, TARC level, eotaxin-3 level, ECP level, and MPO level.
[0201] Embodiment 22. The use according to any one of Embodiments 13-21, wherein the anti-TSLP antibody or antigen-binding fragment thereof is administered at a dose of 12-840 mg, 21-630 mg, 105-630 mg, 210-630 mg, or 210-420 mg each time; preferably, the anti-TSLP antibody or antigen-binding fragment thereof is administered at a dose of 210 mg or 420 mg each time.
[0202] Embodiment 23. The use according to any one of Embodiments 13-22, wherein the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 1 week, every 2 weeks, every 3 weeks, or every 4 weeks; preferably, the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 4 weeks.
[0203] Embodiment 24. The use according to any one of Embodiments 13-23, wherein the subject is administered one or more additional therapeutic agents before, after or simultaneously with receiving the anti-TSLP antibody or its antigen-binding fragment; preferably, the subject has been administered or is being administered one or more additional therapeutic agents before receiving the anti-TSLP antibody or its antigen-binding fragment.
[0204] Embodiment 25. The use according to embodiment 24, wherein the additional therapeutic agent is selected from one or more of glucocorticoids, long-acting β2 receptor agonists, short-acting β2 receptor agonists, IL-1 inhibitors, IL-5 inhibitors, IL-5Rα inhibitors, IL-13 inhibitors, TNF inhibitors, IgE inhibitors, non-steroidal anti-inflammatory drugs, antibiotics, antihistamines, antifungal agents, local decongestants, long-acting muscarinic antagonists and leukotriene antagonists; preferably, the glucocorticoid is selected from one or more of nasal glucocorticoids, inhaled glucocorticoids and systemic glucocorticoids.
[0205] Embodiment 26. The use according to Embodiment 24, wherein the subject has been or is being administered a nasal glucocorticoid before receiving the anti-TSLP antibody or its antigen-binding fragment; preferably, the subject has been or is being administered mometasone furoate nasal spray before receiving the anti-TSLP antibody or its antigen-binding fragment.
[0206] Embodiment 27. The use according to any one of embodiments 13-26, wherein the anti-TSLP antibody or antigen-binding fragment thereof comprises:
[0207] (1) a heavy chain variable region having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:7, and a light chain variable region having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:8, wherein X1 of SEQ ID NO:8 = A or S; or (2) a heavy chain variable region having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:17, and a light chain variable region having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:18.
[0208] Embodiment 28. The use according to any one of embodiments 13-27, wherein the anti-TSLP antibody or antigen-binding fragment thereof comprises:
[0209] (1) a heavy chain having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:9, and a light chain having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:10, wherein X1 of SEQ ID NO:10 = A or S; or
[0210] (2) a heavy chain having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 19, and a light chain having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 20.
[0211] Embodiment 29. The use according to any one of Embodiments 13-28, wherein the anti-TSLP antibody or antigen-binding fragment thereof is formulated with a pharmaceutically acceptable excipient. Example
[0212] For the sake of clarity, the present disclosure is further illustrated with examples, but the examples do not limit the scope of the present disclosure. All reagents used in the present disclosure are commercially available and can be used without further purification.
[0213] The entire contents of the patent application documents with publication numbers WO2021043221A1 or CN113423733A are incorporated into the present disclosure. The heavy chain amino acid sequence of the anti-TSLP antibody in the following examples is shown in SEQ ID NO: 9 of the present disclosure, and the light chain amino acid sequence is shown in SEQ ID NO: 10 of the present disclosure.
[0214] Example 1: Clinical trial A for chronic sinusitis with nasal polyps
[0215] 1. Experimental Design
[0216] This clinical trial includes a 1-week screening period, a 4-week introduction period, a 24-week treatment period, and an 8-week post-treatment follow-up period. During the treatment period, randomization will be performed from day 1 and the trial drug or placebo will be administered until week 24. No drug will be administered in week 24, and the trial drug or placebo will be administered a total of 6 times.
[0217] Mometasone furoate nasal spray As a basic medication. During the lead-in period, the subjects began to use mometasone furoate nasal spray Stop using until the end of clinical trial (EOS) or when treatment is terminated in the clinical trial.
[0218] 2. Selection criteria
[0219] Subjects eligible to participate in this trial must meet the following inclusion criteria:
[0220] (1) Sign the informed consent form before the trial and fully understand the purpose, process and possible adverse reactions of the trial;
[0221] (2) Aged 18-75 (inclusive), regardless of gender;
[0222] (3) Patients with bilateral chronic sinusitis with nasal polyps (CRSwNP) who meet the diagnostic criteria of the "Guidelines for the Diagnosis and Treatment of Chronic Rhinosinusitis in China (2018)"; (4) Patients who have received at least one course of systemic glucocorticoid treatment (0.5-1 mg / kg / day or 15-30 mg / day or equivalent dose of prednisone for at least 5 days) within 2 years before screening, but still have bilateral chronic sinusitis with nasal polyps, and / or have contraindications / intolerance to systemic glucocorticoids, and / or have undergone surgical treatment for nasal polyps within 6 months before screening;
[0223] (5) bilateral nasal polyp score (NPS) ≥5 (maximum score is 8) assessed by nasal endoscopy at screening and randomization, and the score of each nostril ≥2;
[0224] (6) nasal congestion score (NCS) ≥2 at screening and randomization;
[0225] (7) symptoms such as rhinorrhoea and / or hyposmia or loss of smell persisted for more than 8 weeks before screening;
[0226] (8) 22-item Sinus-Nasal Outcome Test (SNOT-22) score ≥30 at screening and randomization;
[0227] (9) Before screening, the subjects had used a relatively stable dose of nasal corticosteroids (INCS) for more than 4 weeks (for subjects who used INCS alternative products instead of intranasal mometasone furoate nasal spray (MFNS) before screening, the subjects were willing to switch to MFNS during the study);
[0228] (10) Subjects with asthma who have started stable doses of inhaled glucocorticoids at least 4 weeks before screening and are able to receive treatment during the entire study period.
[0229] The dose of inhaled glucocorticoids remained unchanged;
[0230] (11) The compliance with the intranasal mometasone furoate nasal spray (MFNS) was greater than 70%, and the compliance with the daily symptom assessment record on the subject's diary card was greater than 70%. Days with missing diary card data were considered as non-compliance with this standard.
[0231] (12) The subjects agreed that they had no plans to have children from the date of signing the informed consent form to 6 months after the last dose, and that they and their sexual partners of childbearing age must take effective non-drug contraceptive measures.
[0232] 3. Drugs and treatment options
[0233] 3.1 Trial drug: Anti-TSLP antibody injection (Specification: 210 mg / 1.75 mL / bottle): During the trial, 4 weeks is one treatment cycle.
[0234] Subcutaneous injection, 210mg or 420mg anti-TSLP antibody was administered once on the first day of each treatment cycle, for a total of 6 times. 3.2 Control drug: Placebo (Specification: 1.75mL / bottle): During the trial, 4 weeks was a treatment cycle, and each treatment cycle was administered by subcutaneous injection.
[0235] The drug is administered once on day 1 of the cycle, for a total of 6 doses.
[0236] 3.3 Basic medication: mometasone furoate nasal spray (Specification: 140 presses / bottle, each press contains 50 μg of mometasone furoate): During the trial, 2 presses are administered in each nostril once a day (total daily dose is 200 μg). If the subject cannot tolerate the drug, the dose can be adjusted to 1 press in each nostril once a day (total daily dose is 100 μg).
[0237] 4. Evaluation Criteria
[0238] Safety evaluation: The NCI-CTC AE 5.0 standard was used to judge the severity of adverse events.
[0239] 5. End point indicators
[0240] (1) Changes in the total score of the nasal polyp score (NPS) assessed by nasal endoscopy at week 24 relative to baseline, including:
[0241] NPS is the sum of the scores of the left and right nostrils evaluated by nasal endoscopy, with a total score ranging from 0 to 8. NPS is scored according to the grade of polyps, with 0 being no polyps, 1 being a small polyp in the middle nasal meatus that does not reach below the lower edge of the middle turbinate, 2 being a polyp that reaches below the lower edge of the middle turbinate, and 3 being a polyp that reaches below the lower edge of the middle turbinate.
[0242] 4 points were large polyps that reached the lower edge of the inferior turbinate or the inner side of the middle turbinate, 5 points were large polyps that completely blocked the inferior nasal cavity;
[0243] (2) Change from baseline in nasal congestion score (NCS) assessed in the subject's diary card at week 24, including:
[0244] NCS uses a 0-3 classification scale, where 0 is no symptoms, 1 is mild symptoms, 2 is moderate symptoms, and 3 is severe symptoms, which is determined by the subject based on the severity of nasal congestion in the past 24 hours; for the determination of baseline values, if the subject collected 4 or more measurements within 7 days before randomization, the average of all collected values will be taken as the baseline value; if the patient subject collected less than 4 measurements within 7 days before randomization, the baseline will be the average of the last 4 measurements before randomization (not limited to the 7 days before randomization). For the determination of NCS after treatment, the average score of the end-of-treatment (EOT) week will be used;
[0245] (3) Change from baseline in the smell loss score assessed in the subject's diary card at Week 24, including:
[0246] The smell loss score is a 3-category score, with 0 being no symptoms, 1 being mild symptoms, 2 being moderate symptoms, and 3 being severe symptoms.
[0247] The subjects assessed the severity of their smell loss on that day;
[0248] (4) Change from baseline in the total nasal symptom score (TSS) assessed in the subject log card at week 24, including:
[0249] The subjects scored nasal congestion, loss of smell, and rhinorrhea (the average of anterior and posterior rhinorrhea) at a fixed time every morning. Each symptom was classified into three categories, with 0 for no symptoms, 1 for mild symptoms, 2 for moderate symptoms, and 3 for severe symptoms. TSS is the sum of the above items, with a score range of 0-9. For the determination of baseline values, if the subject collected 4 or more measurements within 7 days before randomization, the average of all collected values will be taken as the baseline value; if the subject collected less than 4 measurements within 7 days before randomization, the baseline will be the average of the last 4 times before randomization (not limited to the 7 days before randomization). For the determination of TSS after treatment, the average score of the EOT week will be used;
[0250] (5) Changes from baseline in the 22-item SNOT-22 score at week 24, including:
[0251] The SNOT-22 rating scale consists of 22 questions, including three dimensions: physical problems, functional limitations, and emotional consequences. The subjects make their assessments based on their experiences in the past two weeks. The total score of SNOT-22 ranges from 0 to 110, and the lower the score, the less impact sinusitis has on quality of life.
[0252] (6) Change in sinusitis visual analogue scale (VAS) score relative to baseline at week 24, including:
[0253] The VAS score ranges from 0 to 10 points. The subjects subjectively evaluate the overall severity of sinusitis and mark the score on the scale. The higher the score, the greater the impact of sinusitis on the subject's quality of life. According to the score range, the condition is divided into mild (0 to 3 points), moderate (3 to 7 points, not including
[0254] 3 points) and severe (7-10 points, excluding 7 points);
[0255] (7) time to first NP surgery and proportion of subjects who underwent NP surgery;
[0256] (8) time to first use of systemic corticosteroids (SCS) for rescue treatment and the proportion of subjects using SCS for rescue treatment;
[0257] (9) Change from baseline in Lund Mackay score (LMK) assessed by CT at week 24, including:
[0258] Lund Mackay scoring was performed using sinus CT scans, with scores for the left and right sinus systems ranging from 0 to 12 points for each side, with a total score of 0 to 24 points, and was scored by a fixed researcher at the research center. For subjects with a current loss of the ostium sinus complex due to previous surgery, the scorer
[0259] A comprehensive score should be made based on the location of the previous ostio-sinus complex;
[0260] (10) Effects on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) at week 24;
[0261] (11) Changes in nasal peak inspiratory flow (NPIF) at week 24 compared with baseline, including:
[0262] NPIF monitors the subject's nasal flow and assesses the subject's nasal resistance by measuring the maximum inspiratory flow rate of both nostrils, and is most relevant to the subject's subjective feeling of nasal congestion. During each test, the subject is required to measure the nasal peak inspiratory flow rate before using MFNS. The subject should rest for at least 5 minutes before the operation. During the operation, the subject stands and returns the indicator dial of the nasal peak inspiratory flow meter to zero. The subject holds the inspiratory peak flow meter connected to a sealed mask horizontally, exhales to the residual breath position, the mask fits tightly against the cheek without leaking, inhales explosively, removes the mask and reads the reading, and repeats the measurement 3 times. The highest value will be used for evaluation. The baseline NPIF value is defined as the highest NPIF value measured 1 day before the first dose. After treatment, the NPIF uses the highest value measured at the EOT visit;
[0263] (12) the incidence and severity of adverse events (AEs) and serious adverse events (SAEs), as well as abnormal laboratory test indicators;
[0264] (13) Pharmacokinetic indicators: Peak plasma concentration (C max ), valley concentration (C min ), peak time (T max ), area under the plasma concentration-time curve (AUC 0-t ), steady-state peak concentration (C ss-max ), steady-state valley concentration (C ss-min ), mean steady-state plasma concentration (C ss-av ), steady-state peak time (T ss-max ), the area under the steady-state plasma concentration-time curve (AUC0-t ), half-life (t 1 / 2 ), mainly including apparent distribution volume (Vd / F), clearance rate (CL / F), etc.;
[0265] (14) Immunogenicity: The incidence and titer of anti-drug antibodies (ADA) and the incidence of neutralizing antibodies (Nab) in the subjects. If the subject is found to be ADA positive, neutralizing antibodies will be tested.
[0266] (15) Forced expiratory volume in one second (FEV1), forced pulmonary ventilation function (FVC), and forced expiratory flow in CRSwNP subjects with asthma
[0267] 25-75% (FEF25-75%) change from baseline;
[0268] (16) Changes from baseline in ACQ-6 scores in CRSwNP subjects with comorbid asthma;
[0269] (17) Changes in peripheral blood total IgE and blood eosinophil count relative to baseline at week 24;
[0270] (18) Changes in peripheral blood eosinophil cationic protein (ECP), myeloperoxidase (MPO), and thymic activation-regulated chemokine (TARC) relative to baseline at week 24.
[0271] Example 2: Clinical trial B for chronic sinusitis with nasal polyps
[0272] 1. Experimental Design
[0273] This clinical trial includes a 1-week screening period, a 28-week treatment period, and an 8-week post-treatment follow-up period. During the treatment period, randomization will be performed and the trial drug will be administered from day 1 until week 28. No trial drug will be administered in week 28, and the trial drug will be administered a total of 7 times.
[0274] Mometasone furoate nasal spray As a basic medication. Subjects started using mometasone furoate nasal spray during the screening period. Stop using until the end of clinical trial (EOS) or when treatment is terminated in the clinical trial.
[0275] 2. Selection criteria
[0276] Subjects eligible to participate in this trial must meet the following inclusion criteria:
[0277] (1) Sign the informed consent form before the trial and fully understand the purpose, process and possible adverse reactions of the trial;
[0278] (2) Aged ≥ 18 years, regardless of gender;
[0279] (3) Participating in the clinical trial described in Example 1 and meeting the following criteria a) or b):
[0280] a) The subjects completed the prescribed treatment as required by the protocol and completed the EOT visit at week 24;
[0281] b) The subject withdraws early and completes the early withdrawal visit according to the protocol, and the factors that lead to the subject's early termination have disappeared or no longer affect the subject's participation in this study as assessed by the investigator and the sponsor;
[0282] (4) Subjects had used a stable dose of INCS for more than 4 weeks before screening (for subjects who used INCS alternative products instead of intranasal MFNS before screening, the subjects were willing to switch to MFNS during the study);
[0283] (5) The subjects agree not to have any fertility plans from the date of signing the informed consent form to 6 months after the last dose, and must take effective non-drug contraceptive measures with their sexual partners of childbearing age.
[0284] 3. Drugs and treatment options
[0285] 3.4 Trial drug: Anti-TSLP antibody injection (Specification: 210 mg / 1.75 mL / bottle): During the trial, 4 weeks is one treatment cycle.
[0286] Subcutaneous injection, 210 mg or 420 mg of anti-TSLP antibody is administered once on the first day of each treatment cycle, for a total of 7 doses. 3.5 Basic medication: mometasone furoate nasal spray (Specification: 140 presses / bottle, each press contains 50 μg of mometasone furoate): During the trial period,
[0287] Use 2 presses in each nostril once a day (total daily dose is 200 μg). If the subject cannot tolerate it, the dose can be adjusted to 1 press in each nostril once a day (total daily dose is 100 μg).
[0288] 4. Evaluation Criteria
[0289] Safety evaluation: The NCI-CTC AE 5.0 standard was used to judge the severity of adverse events.
[0290] 5. End point indicators
[0291] (1) the frequency of treatment-emergent adverse events (TEAEs);
[0292] (2) the frequency of serious adverse events (SAEs) during treatment;
[0293] (3) abnormal laboratory test indicators during treatment;
[0294] (4) change in nasal polyp score compared with the baseline (the baseline values of the clinical study described in Example 1 and this study, respectively);
[0295] (5) Change in nasal congestion score (NCS) relative to baseline (the baseline values of the clinical study described in Example 1 and this study, respectively);
[0296] (6) the change in the smell loss score relative to the baseline (the baseline value of the clinical study described in Example 1 and the baseline value of this study, respectively);
[0297] (7) change in total nasal symptom score (TSS) relative to baseline (the baseline values of the clinical study described in Example 1 and this study, respectively);
[0298] (8) Change in the 22-item Sinus-Nasal Outcome Test (SNOT-22) score relative to baseline (the baseline values of the clinical study described in Example 1 and this study were used respectively);
[0299] (9) change in the sinusitis visual analogue scale (VAS) relative to the baseline (the baseline values of the clinical study described in Example 1 and this study, respectively);
[0301] (10) Change in Lund Mackay score (LMK) assessed by CT relative to baseline (the baseline values of the clinical study described in Example 1 and this study were used respectively);
[0303] (11) Immunogenicity: The incidence and titer of anti-drug antibodies (ADA) and the incidence of neutralizing antibodies (Nab) in the subjects. If the subject is found to be ADA positive, neutralizing antibodies will be tested.
[0304] The scoring methods for the above indicators are carried out with reference to Example 1.
Claims
1. Use of an anti-TSLP antibody or an antigen-binding fragment thereof in the preparation of a medicament for treating chronic sinusitis in a subject in need thereof, wherein: (1) The anti-TSLP antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises the amino acid sequence of HCDR1 in SEQ ID NO:7, HCDR2 comprises the amino acid sequence of HCDR2 in SEQ ID NO:7, HCDR3 comprises the amino acid sequence of HCDR3 in SEQ ID NO:7, LCDR1 comprises the amino acid sequence of LCDR1 in SEQ ID NO:8, LCDR2 comprises the amino acid sequence of LCDR2 in SEQ ID NO:8 and LCDR3 comprises the amino acid sequence of LCDR3 in SEQ ID NO:8, wherein X1 of SEQ ID NO:8 = A or S; (2) the anti-TSLP antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises the amino acid sequence of HCDR1 in SEQ ID NO: 17, HCDR2 comprises the amino acid sequence of HCDR2 in SEQ ID NO: 17, HCDR3 comprises the amino acid sequence of HCDR3 in SEQ ID NO: 17, LCDR1 comprises the amino acid sequence of LCDR1 in SEQ ID NO: 18, LCDR2 comprises the amino acid sequence of LCDR2 in SEQ ID NO: 18 and LCDR3 comprises the amino acid sequence of LCDR3 in SEQ ID NO: 18; (3) The anti-TSLP antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 of the heavy chain variable region as shown in SEQ ID NO:7, and LCDR1, LCDR2 and LCDR3 of the light chain variable region as shown in SEQ ID NO:8, wherein the X1=A or S; or (4) The anti-TSLP antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 of the heavy chain variable region shown in SEQ ID NO: 17, and LCDR1, LCDR2 and LCDR3 of the light chain variable region shown in SEQ ID NO:
18.
2. Use of an anti-TSLP antibody or an antigen-binding fragment thereof in the preparation of a medicament for treating chronic sinusitis in a subject in need thereof, wherein: The anti-TSLP antibody or antigen-binding fragment thereof comprises: (1) a HCDR1 comprising the amino acid sequence of SEQ ID NO:1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:2, a HCDR3 comprising the amino acid sequence of SEQ ID NO:3, a LCDR1 comprising the amino acid sequence of SEQ ID NO:4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:6; or (2) HCDR1 comprising the amino acid sequence shown in SEQ ID NO:11, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:12, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:
16.
3. The use according to claim 1 or 2, wherein The chronic sinusitis is chronic sinusitis with nasal polyps or bilateral chronic sinusitis with nasal polyps.
4. The use according to any one of claims 1 to 3, wherein The subject further suffers from asthma.
5. The use according to any one of claims 1 to 4, wherein The anti-TSLP antibody or antigen-binding fragment thereof is administered at a dose of 12-840 mg, 21-630 mg, 105-630 mg, 210-630 mg, or 210-420 mg each time; preferably, the anti-TSLP antibody or antigen-binding fragment thereof is administered at a dose of 210 mg or 420 mg each time.
6. The use according to any one of claims 1 to 5, wherein The anti-TSLP antibody or antigen-binding fragment thereof is administered once every 1 week, every 2 weeks, every 3 weeks, or every 4 weeks; preferably, the anti-TSLP antibody or antigen-binding fragment thereof is administered once every 4 weeks.
7. The use according to any one of claims 1 to 6, wherein The subject is administered one or more additional therapeutic agents before, after or simultaneously with the anti-TSLP antibody or antigen-binding fragment thereof; preferably, the subject has been administered or is being administered one or more additional therapeutic agents before receiving the anti-TSLP antibody or antigen-binding fragment thereof.
8. The use according to claim 7, wherein The additional therapeutic agent is selected from one or more of glucocorticoids, long-acting β2 receptor agonists, short-acting β2 receptor agonists, IL-1 inhibitors, IL-5 inhibitors, IL-5Rα inhibitors, IL-13 inhibitors, TNF inhibitors, IgE inhibitors, non-steroidal anti-inflammatory drugs, antibiotics, antihistamines, antifungal agents, local decongestants, long-acting muscarinic antagonists and leukotriene antagonists; preferably, the glucocorticoid is selected from one or more of nasal glucocorticoids, inhaled glucocorticoids and systemic glucocorticoids.
9. The use according to claim 7, wherein: The subject has been or is being administered nasal glucocorticoids before receiving the anti-TSLP antibody or antigen-binding fragment thereof; preferably, the subject has been or is being administered mometasone furoate nasal spray before receiving the anti-TSLP antibody or antigen-binding fragment thereof.
10. The use according to any one of claims 1 to 9, wherein The anti-TSLP antibody or antigen-binding fragment thereof comprises: (1) a heavy chain variable region having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:7, and a light chain variable region having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:8, wherein X1 of SEQ ID NO:8 = A or S; or (2) a heavy chain variable region having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 17, and a light chain variable region having an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 18.
